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SNA  Sympathetic nerve activity 
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VMH  Ventromedial hypothalamic nucleus
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ABSTRACT 
Introduction 
Leptin, resistin and insulin are hormones that circulate in the blood and cross the blood brain 
barrier. In the brain, they are thought to activate specific regions which play important roles 
in energy homeostasis and cardiovascular regulation. The plasma levels of these hormones 
have been shown to be elevated in overweight and obese conditions, and an increased 
sympathetic nerve activity (SNA) is also observed in these conditions. In addition, leptin, 
resistin and insulin plasma levels are strongly correlated with increases in blood pressure 
suggesting that these hormones may have cardiovascular effects. In high fat diet (HFD), the 
effects of leptin on renal sympathetic nerve activity (RSNA) are well known. However, the 
effects of insulin are little known, and the effects of resistin are not known. Since leptin, 
resistin and insulin levels are increased significantly in obesity and each of these hormones 
alone can increase RSNA, the question arises as to whether there is an interaction between 
these hormones on cardiovascular regulation. 
Thus, the general aim of this thesis was to compare the effects of leptin, resistin and insulin 
alone and in combination on RSNA, mean arterial pressure (MAP) and heart rate (HR) in rats 
fed a normal chow diet (ND) or HFD. 
Methods 
Male Sprague-Dawley rats were divided into two groups one fed a ND and the other fed a 
HFD for approximately 8-10 weeks. Food intake, caloric intake and body weight were 
monitored over the duration of the feeding regime. At the end of the feeding regime, the 
whole body fat mass was calculated. On the day of experiments, rats were anaesthetized with 
isoflurane gas (initially 5% then 2%) in O2. Anaesthesia was maintained by intravenous (IV) 
injection of urethane (1.4-1.6 g/kg) followed by supplemental doses of 0.05 ml (of a 25% 
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solution). The depth of anaesthesia was determined by ensuring the lack of corneal and pedal 
reflexes. Saline (5 µl), leptin (7 µg/5 µl), resistin (7 µg/5 µl) and insulin (500 mU/5 µl) were 
administered intracerebroventricularly (ICV) and RSNA, MAP and HR were monitored and 
recorded before and for 3 hours after hormone administration. Additionally, the potential 
central sites of action of the interaction of (leptin + resistin) and (leptin + insulin) were 
investigated in rats fed a ND. In these groups, the brains were removed at the end of the 
experiments and processed immunohistochemically to detect the protein Fos, a marker of 
increased neuronal activation. 
Results 
In chapter 3, ICV administration of the combination of leptin and resistin in rats fed a ND 
produced significant increases in RSNA over time compared to each hormone alone 
(P<0.0001). In addition, the central administration of leptin and resistin together increased 
Fos production in the arcuate nucleus (ARC) compared to each hormone alone. This finding 
suggests that the ARC may be a key central site in which leptin and resistin together induced 
greater effects on the RSNA response than either leptin or resistin alone. Therefore, increases 
in leptin and resistin levels may contribute to the abnormal elevation in RSNA seen in 
overweight/obese conditions. 
In chapter 4, in rats fed a ND the increases in RSNA following ICV injection of leptin and 
insulin combined were significantly greater than each hormone alone (P<0.0001). The 
number of Fos-positive cell nuclei was only significantly greater in ARC following ICV 
leptin and insulin together compared to leptin alone, resistin alone or saline. This finding 
suggests that sympathetic activity to the kidney is greatly increased when leptin and insulin 
levels are elevated. In addition, the ARC might be the site mediating this interaction of leptin 
and insulin. 
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In chapter 5, ICV administration of resistin increased RSNA significantly in rats fed a HFD. 
This effect was similar to ND group. Moreover, in the HFD group when leptin and resistin 
were administered in combination, RSNA increased significantly more compared to each 
hormone alone. The greater increases in the HFD following leptin and resistin combined was 
not significantly different compared to the response in rats fed the ND. This result suggests 
that leptin and resistin elevate the sympathetic activity response to the kidney, and this is not 
affected by a diet high in fat. 
In chapter 6, in rats fed a ND the administration of resistin and insulin in combination did not 
increase the RSNA, and this response was significantly different compared to either hormone 
alone. In rats fed a HFD, RSNA fell significantly. These results suggest that HFD markedly 
alters the RSNA response and there may be a negative interaction when resistin and insulin 
are combined. 
In chapter 7, in rats fed a HFD the combination of leptin and insulin produced significant 
reductions in RSNA compared with either hormone alone. These results suggest that HFD 
can markedly affect the RSNA response of the combination of leptin and insulin compared to 
that seen in ND. Therefore, this result suggests that HFD may influence the RSNA response 
to leptin and insulin combined. 
Summary and Conclusion 
The results show that ICV administration of leptin + resistin increases SNA to the kidney in 
ND and HFD animals. The effects of leptin and insulin in combination showed that HFD 
significantly reduced the RSNA responses induced by these hormones in contrast to the 
increases seen in ND. When resistin and insulin were combined, the response to RSNA was 
not increased in ND and in HFD, RSNA fell markedly. 
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Together, these data suggest that in HFD the presence of insulin with resistin or leptin may 
result in a negative interaction on RSNA. However, the positive interaction in HFD seen with 
resistin and leptin might overcome any negative interaction of insulin with resistin or leptin. 
Therefore, the interaction between leptin and resistin may contribute to the abnormal 
elevation of RSNA, seen in overweight /obese conditions. 
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1 Chapter 1: Introduction 
1.1 OBESITY 
Weight gain induced by high fat diet (HFD) can lead to obesity, which is becoming a major 
health problem worldwide and is rapidly increasing in developed countries (1, 2). According 
to the Australian Institute of Health and Welfare, in 2014-15 approximately two thirds of 
adult Australians are either obese or overweight (3). Moreover, in the USA, obesity and being 
overweight result in approximately 300,000 deaths every year (4). In addition, statistics 
indicate that if the current trend towards weight gain continues, by 2025, more than 80% of 
the adult population in developed countries will be either obese or overweight (5). Many 
studies have shown that weight gain leads to a variety of health complications such as 
cardiovascular diseases, metabolic disorders and type-2 diabetes (6, 7). 
1.2 CARDIOVASCULAR DISEASE IN OBESITY 
Moderate and severe obesity is a well-known risk factor for many cardiovascular 
complications such as hypertension. Clinical studies have shown that increased food 
consumption and caloric intake leads to increases in blood pressure (6-13). Conversely, other 
studies suggest that decreasing weight by a low-calorie diet can lead to reductions in blood 
pressure in humans (14, 15). Studies in animal models, including rodents and rabbits, fed a 
HFD show increases in blood pressure (1, 16-23). For example, some studies have 
investigated the effects of HFD on Sprague-Dawley rats. These rats were fed a HFD and over 
time they were observed to develop obesity and arterial hypertension (21, 22). Rats fed a 
HFD can be segregated into obese-resistant, which do not develop obesity when fed a HFD, 
and obese-prone groups, which do develop obesity when fed a HFD and develop 
hypertension (24, 25). Therefore, there is an association of obesity induced by high fat 
consumption and elevated blood pressure. Interestingly, studies have shown that one of the 
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common drivers of high blood pressure is an overactivity of the sympathetic nervous system 
(7, 26). 
1.3 SYMPATHETIC NERVE ACTIVITY AND CARDIOVASCULAR 
COMPLICATIONS 
Sympathetic activation to the cardiovascular organs can lead to increases in blood pressure by 
acting on the heart, kidneys and vasculature. Overactivity of sympathetic nerve activity 
(SNA) to the vasculature leads to peripheral vasoconstriction, whereas increased SNA to the 
kidneys leads to increased renal tubular sodium reabsorption potential changes in renal 
filtrate and function, as well as activation of the renin angiotensin system (7, 26). SNA to the 
heart leads to increased heart rate (HR), stroke volume and cardiac output (27). Together 
these mechanisms mediate the ability of sympathetic overactivity to increase blood pressure. 
In animal models, it possible to measure directly SNA. For example, to measure SNA 
contributing to vasoconstriction, the nerves that innervate blood vessels of the hindlimb 
muscles can be recorded from lumbar sympathetic nerve activity (LSNA) (28). In addition, 
kidneys play a major role in long-term regulation of blood pressure. The nerves can influence 
the diameter of the efferent and the afferent arterioles, and the sympathetic nerves can induce 
the release of hormones from the renal tissue, such as renin (29). Therefore, recording renal 
sympathetic nerve activity (RSNA) gives an indication of sympathetic outflow to an organ of 
key importance to cardiovascular regulation. Thus, it is vital to study what hormones 
influence the RSNA, as this may underpin the increased level of RSNA associated with high 
fat feeding. 
The pathophysiology of obesity is complex where activation of the central nervous system 
(CNS) is one of the multipotential mechanisms that can lead to obesity-induced hypertension 
(30, 31). Body mass index in obesity is correlated with the level of SNA, or norepinephrine 
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(NE) spillover which is a measure of SNA (26), or increased levels of total plasma NE, which 
is a general indicator of sympathetic activation (32). Moreover, it has been found that renal 
NE spillover accounted for over a half of the total plasma NE in hypertensive patients (33, 
34), suggesting that RSNA might be a major contribute to obesity-induced hypertension (35-
37). An increase in SNA to other cardiovascular organs has also been observed in obesity 
(35, 38). Several studies have shown that obese patients have increased muscle SNA, a 
measure of SNA to the muscle vasculature, compared to normal patients (37). 
Furthermore, elevated SNA has been linked to hypertension in animal models of obesity. For 
example, it has been shown that in rabbits fed a HFD there are increases in plasma NE, mean 
arterial pressure (MAP) and HR (17, 39, 40). By week 3 of feeding these rabbits showed 
significant increases in SNA to the kidney (17), supporting the view that activation of SNA in 
obesity can lead to hypertension (35, 38, 40, 41). 
1.4 ADIPOKINES AND INSULIN 
Obesity can be defined by the amount of adipose tissue stored in the body (42). Recent 
studies also highlight that adipose tissue has additional roles other than the storage of fat and 
those roles include endocrine functions (43, 44). Adipose tissue releases chemical mediators, 
which include hormones such as leptin and resistin, which are referred to as adipokines (45). 
The level of adipokines such as leptin and resistin are significantly increased with the 
increase in weight gain associated with obesity or overweight conditions (46-49). These 
hormones can influence metabolic function by regulating the balance between food intake 
and energy expenditure (43). They also play a major role in the regulation of cardiovascular 
function by influencing SNA (50, 51). 
Insulin, although not being an adipokine, is another hormone that has similar effects to leptin 
and resistin, in terms of metabolic function (52). It also contributes to cardiovascular 
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regulation by influencing SNA (53, 54). Therefore these hormones may be linked to obesity-
induced cardiovascular complications. 
Obesity causes the development of resistance to leptin and insulin, in terms of their effects on 
metabolic function (55, 56). However, the effects of leptin on RSNA in obesity or overweight 
conditions are not affected, whilst an effect on insulin is controversial (57, 58). The effect of 
resistin on SNA with HFD is unknown. Therefore, there is a gap in our knowledge in 
understanding the effects of HFD in the response to resistin on SNA, together with any 
interactions of leptin, resistin or insulin in combination on SNA. 
1.4.1 Leptin 
Leptin is a 16kDa polypeptide, which was first discovered in 1994. Leptin is found in adipose 
tissue, the primary site of leptin production, although other tissues such as skeletal muscle, 
liver and stomach also can produce leptin (59-61). The amount of body fat is the main factor 
contributing to the level of leptin in the blood (62). Leptin levels typically increase after a 
meal and decrease during fasting, and increases in plasma leptin levels eventually lead to a 
loss of body weight (63). But there is also evidence to suggest that leptin is produced by the 
brain (64, 65). Leptin has been shown to cross the blood-brain barrier (66). The receptors for 
leptin are found to be widely distributed throughout different regions of the hypothalamus, 
such as the arcuate nucleus (ARC) and the paraventricular nucleus (PVN) (57, 67). In the 
CNS, leptin acts through the hypothalamus by activating its receptors to regulate food intake, 
energy expenditure, and cardiovascular regulation (68-71). It has been shown that leptin can 
control and regulate appetite (72), energy expenditure through thermogenesis, and 
cardiovascular regulation through sympathetic nerve activation (18, 73). Since its discovery, 
leptin has been linked to cardiovascular diseases (74-76). In the next section, I discuss the 
metabolic and cardiovascular actions of leptin. 
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1.4.1.1 Role of leptin in metabolic function 
Leptin plays a major role in the control of feeding behaviour and energy balance. Weight gain 
leads to increased plasma leptin levels, and leptin acts centrally in the brain through specific 
receptors in the hypothalamus to decrease food intake and increase energy expenditure (62, 
65, 69, 70). Typically, leptin levels are observed to be higher at night than during the day, so 
that a greater response of leptin occurs to a meal at night time than during the day. It has also 
been shown that during fasting periods, plasma leptin levels are reduced (63). 
Experimentally, acute and chronic administration of leptin in animals resulted in decreased 
body weight (18, 77-79). This occurs through actions in the brain since 
intracerebroventricular (ICV) injection of leptin into rats resulted in a reduction in food 
intake by approximately 24% (80). Treatment with leptin resulted in a higher body 
temperature compared with non-treated animals, suggesting that leptin elicits an increased 
thermogenesis resulting in an increased energy expenditure (81). Moreover, leptin treatment 
in rats has been shown to reduce visceral fat, suggesting that leptin results in fat redistribution 
(82). Finally, leptin treatment in patients has been found to reduce truncal and visceral fat 
mass (83, 84). The findings, together, show that leptin plays an important role in a metabolic 
function via reducing food intake and increasing energy expenditure in response to feeding. 
In overweight and obese conditions, where the amount of fat tissue is elevated, plasma leptin 
levels are found to be significantly elevated (79, 85-87). HFD consumption in humans and 
animal models increases plasma levels of leptin and also cause weight gain (18, 88). 
Moreover, body weight and food intake have been shown to be minimally affected by leptin 
in animals fed a HFD (18), suggesting HFD promotes the development of resistance to the 
effects of leptin in terms of reducing body weight and increasing energy expenditure (18). 
This has been supported by studies, which show that leptin is much less effective in reducing 
appetite and food intake in animals fed a HFD (17, 58, 89). In addition, leptin treatment in 
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human overweight patients fails to reduce weight or suppress appetite (90, 91). In fact, leptin 
has been shown to play an important role in regulating metabolic function in healthy subjects, 
whereas in subjects fed a HFD, leptin’s ability to reduce food intake is markedly attenuated. 
1.4.1.2 Cardiovascular impact of leptin 
Many previous studies have shown that leptin does not only have actions on metabolic 
function, but it also plays an important role in cardiovascular regulation (92-94). Studies 
show that mutations in the genes for leptin or leptin receptors in humans and rodents can 
prevent hypertension (95, 96). These mutations have been shown to result in hypotension and 
a reduced renin-angiotensin system (97). Furthermore, rodents with leptin deficiency have 
been shown to have lower blood pressure than wild type rodents (96, 98). This, therefore, 
suggests that leptin plays an important role in regulating blood pressure. 
1.4.1.3 Effects of leptin on blood pressure and heart rate 
Many studies have investigated the effects of leptin administration on blood pressure. For 
example, the ICV administration of leptin in male Wistar rats increased MAP by a maximum 
of 15% from baseline. However, no statistically significant changes were observed in the HR 
(99). In Sprague-Dawley rats, the acute ICV administration of leptin also showed increases in 
arterial blood pressure but not HR (100, 101). In rabbits, the acute central administration of 
leptin has also been shown to result in increases in MAP (17, 102). This, therefore, shows 
that the acute short-term central administration of leptin results in increasing MAP, which 
suggests that leptin, plays a central role in regulating blood pressure. 
In long-term studies, in male Sprague-Dawley rats, intravenous (IV) infusion of leptin for 12 
days increased blood pressure significantly using a high dose of leptin, whereas only slight 
increases were observed at a lower dose. HR also increased at both the lower and the higher 
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does (103, 104). The increases in blood pressure and HR were attenuated dramatically upon 
cessation of leptin infusion (103, 104). However, short-term IV infusion of leptin for three 
hours, did not change MAP (105, 106). Together, the studies show that long-term peripheral 
infusion of leptin increases blood pressure, suggesting that leptin may also be playing a role 
in regulating blood pressure peripherally. 
Surprisingly, in contrast to a metabolic function, leptin has been shown to increase blood 
pressure in overweight and obese conditions. In diet-induced obese (DIO) mice, acute and 
chronic treatment with leptin has been shown to result in significant increases in MAP and 
those increases were similar in both lean and DIO mice (18). Moreover, rabbits on a HFD 
have been observed to show significant elevations in MAP following acute leptin 
administration (17). In Sprague-Dawley rats, chronic long-term administration of leptin 
increased MAP and HR significantly (107). Furthermore, studies in obese leptin-deficient 
mice show lower levels of arterial pressure compared to lean mice (98), suggesting the 
importance of leptin in maintaining an elevated blood pressure. Thus, leptin maintains its 
actions of increasing blood pressure in overweight and obese conditions. 
1.4.1.4 Role of leptin in sympathetic nerve activity 
The sympathetic nervous system plays an important role in the regulation of the 
cardiovascular system by affecting the nerves to the kidney and blood vessels, as well as in 
the regulation of metabolic function by influencing sympathetic nerve activity to brown 
adipose tissue (BAT SNA). In overweight and obese conditions, the level of NE in human 
patients has been observed to significantly increase, suggesting an activation of the 
sympathetic nervous system (26, 108). More directly, leptin acts centrally through specific 
regions of the brain, including those, which contain many of the premotor sympathetic 
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neurones, which regulate cardiovascular function as well as metabolic function (100). This is 
discussed in the following section. 
Lumbar sympathetic nerve activity 
Leptin has been shown to regulate cardiovascular function through the activation of the 
sympathetic nervous system. Acute central administration of leptin in rats results in 
significant increases in SNA to the skeletal muscle blood vessels (lumbar) (99, 109). 
Moreover, chronic IV administration of leptin in rats also resulted in dose-dependent 
increases in LSNA (105). 
In DIO and HFD fed animals, the LSNA responses to leptin are attenuated (18, 58). For 
example, ICV administration of leptin in DIO mice showed reductions in LSNA compared to 
lean mice (18, 58). Moreover, the IV administration of leptin elicited an attenuated LSNA 
response in HFD fed mice compared to a normal chow diet (ND) (18, 58). These findings 
suggest that in overweight or obese conditions there is resistance to the actions of leptin on 
LSNA, just as there is for leptin’s effects on BAT SNA. 
Renal sympathetic nerve activity 
Leptin has been shown to induce significant increases in RSNA through acting centrally in 
the hypothalamus (100). This is seen in rats (99, 100, 109), rabbits (102), and also in mice 
(18, 87, 100, 110). Moreover, the IV administration of leptin in rats has been shown to elicit 
increases in RSNA (105, 106). These increases in RSNA by central and peripheral 
administration suggest that the actions of leptin are elicited centrally. This is confirmed by 
microinjection of leptin into many cardiovascular regions such as the PVN of the 
hypothalamus, the ventromedial hypothalamic nucleus (VMH), the dorsomedial 
hypothalamic nucleus (DMH), the nucleus tractus solitaries (NTS), the rostral ventrolateral 
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medulla (RVLM), and the ARC in rats which elicited increases in RSNA (73, 100, 101, 111, 
112). 
The sympathetic activation to the kidney in response to leptin was not attenuated by HFD 
(18, 58, 79, 87, 110). In DIO mice, the acute administration of leptin after 20 weeks of 
feeding on a HFD resulted in increases in RSNA that were similar to lean mice (58). 
Similarly, such an effects were seen in mice fed a HFD for 10 only weeks (18). In rabbits fed 
a HFD there were significant increases in RSNA after 3 weeks of feeding and the increase in 
RSNA was evident within 7 days of the diet consumption (17). In all cases, the elevations in 
RSNA induced by leptin in HFD fed animals were similar to the respective response seen in 
animals fed a ND (17). Therefore, the data suggests that the central effects of leptin on RSNA 
are selectively resistant to the attenuating actions in overweight or obese conditions that have 
been observed with LSNA and BAT SNA. 
Sympathetic nerve activity to brown adipose tissue 
Leptin is well known for its role in regulating food intake and energy expenditure through 
thermogenesis. Thermogenesis is a process where the temperature is increased through the 
activation of BAT SNA (113). The key area of importance in the brain for regulation of 
thermogenesis by leptin is the hypothalamus (114, 115). This is exemplified by studies with 
IV and ICV administration of leptin in rats that show an increase in BAT SNA (100, 105, 
106). Since injection of leptin directly into the ARC in rats elicited increases in BAT SNA 
(100). It would suggest that the ARC is the key site of action for leptin’s effect on BAT SNA. 
In overweight and obese conditions, the effects of leptin on BAT SNA are reduced (18, 58). 
For example, BAT SNA in DIO mice has been shown to be attenuated following the acute 
ICV administration of leptin (18, 58). Moreover, the IV administration of leptin in HFD fed 
mice has also failed to increase the BAT SNA (18, 58). Together, these findings suggest that 
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a HFD can lead to obesity-linked induction of resistance to the effects of both systemic and 
central administration of leptin on BAT SNA. 
Mechanisms mediating the effects on sympathetic nerve activity 
The second messenger enzyme Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) plays 
a major role in regulating RSNA responses induced by leptin (58). Acute administration of a 
PI3K inhibitor (LY294002) ICV results in the attenuation of the elevation of RSNA induced 
by leptin (58), indicating a key role of central PI3K in mediating the RSNA induced by the 
infusion of leptin in the CNS (58). In addition, melanocortin receptors (MCR) in the 
hypothalamus also mediates the effects of leptin on RSNA (58, 110). As shown by studies in 
which the presence of the MC3/4R antagonist (SHU9119) in the brain significantly attenuates 
the increases in RSNA induced by central leptin (58, 110). Together these results suggest that 
leptin activates Pro-opiomelanocortin (POMC) neurons resulting in the release of α-MSH that 
in turn, activates MC3/4R centrally, and the activation of the second messenger PI3K, to 
induce leptin’s effect on RSNA. 
1.4.2 Resistin  
Resistin is an adipokine, which was discovered in mice in 2001 (47). It was called resistin 
because of its ability to induce resistance to the action of insulin (47). Resistin is secreted 
mainly by adipose tissue in rodents (47, 116, 117). In humans, resistin is produced mainly by 
macrophages, which infiltrate adipose tissue (118-120). In addition to adipose/macrophages 
in adipose tissue, resistin has also been found to be expressed in other tissues such as skeletal 
muscles and pancreas in humans and rodents (47, 121). Messenger RNA of resistin has been 
observed to be expressed in rodent brains in the hypothalamus, and it is also been seen human 
cerebrospinal fluid (CSF) (47, 121-125). To date there has not been any studies reporting the 
effects of resistin microinjected into specific brain nuclei, nor there has been any studies 
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reporting sites in the brain where resistin can potentially act. Furthermore, resistin receptors 
has not been identified yet. The plasma levels of resistin, in normal conditions, are reported to 
be approximately 7.3-14.3 ng/ml and 35.7-42.9 ng/ml, in humans and rodents respectively 
(48, 126). However, resistin levels were found to be increased significantly in obese and DIO 
rodent models (127). In addition, there was a positive correlation between human resistin 
plasma levels and obesity (128, 129). Plasma levels of resistin are reduced during fasting; in 
contrast, they are increased upon feeding (47, 130, 131). As the levels of resistin change in 
relation to food intake, it suggests that resistin regulates energy homoeostasis (132, 133). 
1.4.2.1 Metabolic impact of resistin 
Resistin has, indeed, been shown to play a role in energy homeostasis (47). The effects of 
central resistin administration on food intake have been investigated. ICV administration of 
resistin has been shown to have anorectic effects on food intake for approximately 90 minutes 
after resistin injection (125). These effects are associated with resistin’s ability to decrease 
neuropeptide Y gene expression in the hypothalamus (134). Furthermore, resistin has been 
shown to alter energy expenditure. An important component of energy expenditure is 
thermogenesis in BAT (135). ICV injection of resistin has been shown to decrease BAT SNA 
(136). Therefore, together the evidence suggests that resistin plays an important role in 
regulating metabolic function, by suppressing food intake and decreasing energy expenditure. 
1.4.2.2 Resistin in obesity  
The plasma levels of resistin are increased in obesity. For example, in humans, serum levels 
of resistin in obesity were significantly higher compared to lean individuals and were 
positively correlated with body mass index (48) and abdominal fat depots (137). Similarly, in 
obese animal models, circulating levels of resistin were significantly higher compared with 
lean controls (127). In contrast weight loss results in a reduction of resistin plasma levels 
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(138). Thus, studies to date provide evidence of a positive correlation between resistin serum 
level and obesity.  
As mentioned earlier, resistin has also been shown to induce insulin resistance. This occurs 
through attenuation of the phosphorylation of the insulin receptor (139). Several studies have 
identified a positive correlation between serum resistin levels and the degree of insulin 
resistance in vivo and in vitro (140, 141). This action of resistin has suggested that resistin 
may play an important role in the development of diabetes. In humans, it has been shown that 
subjects with type-two diabetes show an increase of approximately 20% in serum resistin 
levels (142). Furthermore, the infusion of resistin in humans has been shown to decrease 
insulin sensitivity (143), and insulin-stimulated glucose uptake (144). Therefore, resistin is 
implicated in the complications of obesity and metabolic syndrome by reducing insulin 
sensitivity. 
1.4.2.3 Cardiovascular impact of resistin 
Studies have linked resistin with cardiovascular complications. Increasing serum resistin 
levels are associated with high blood pressure and cardiovascular disease (47, 145-149). 
Resistin levels may also have a prognostic value since it has been found that in young healthy 
patients with a family history of hypertension show elevated plasma resistin levels (150). 
Although there appears a strong link between resistin plasma levels and hypertension, the 
contribution of resistin to hypertension is still to be clarified. 
1.4.2.4 Effects of resistin on arterial pressure and heart rate 
Resistin effects on blood pressure are little known. Only one study has investigated the role 
of acute resistin administration, and it showed that acute ICV administration of resistin in rats 
did not change MAP or HR (136). However, chronic resistin administration showed that in 
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mice the IV injection of resistin for six days significantly elevates MAP and HR (151). This 
effect on blood pressure could arise from a sufficiently activated response of the sympathetic 
nervous system, as acute administration of resistin has been shown to increase SNA (51, 
136). Thus, only two studies have reported the effects of resistin on MAP or HR and these 
have been in animals fed a ND. In overweight/obesity conditions, the effects of resistin have 
not been investigated yet. 
1.4.2.5  Role of resistin on sympathetic nerve activity 
The effects of resistin on SNA are not well known. Currently, only tow studies have 
examined the effects of resistin on SNA. This will be discussed in detail in the next section. 
Lumbar sympathetic nerve activity 
LSNA is important for the regulation of the hindlimb skeletal muscle vasoconstriction. 
Currently only Kosari et al. have investigated the effects of resistin on LSNA (136). In 
normal male Sprague-Dawley rats, acute administration of resistin into the lateral cerebral 
ventricle significantly increased LSNA when compared with control rats (136). This 
sympatho-excitatory effect of resistin is similar to the response seen with leptin (99, 105, 
109). 
Renal sympathetic nerve activity 
Resistin has been shown to elevate RSNA. Acute administration of resistin in normal rats 
results in a significant increase in RSNA within 15 min, with a maximum increase in RSNA 
of 40% compared to rats treated with the vehicle alone (51). This study is the only one 
performed to date with resistin. The sympatho-excitatory response to resistin is similar to that 
seen with leptin (87, 99-102). 
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Sympathetic nerve activity to brown adipose tissue 
BAT is important for thermogenesis and energy expenditure. Therefore by regulating BAT 
SNA, thermogenesis and energy expenditure is regulated (113, 152). It has been 
demonstrated that acute administration of resistin into the lateral cerebral ventricle in normal 
rats resulted in significantly decreased BAT SNA (136). This, therefore, suggests that resistin 
acting in the brain can reduce thermogenesis and energy expenditure. 
Mechanisms mediating changes in sympathetic nerve activity induced by resistin 
Extracellular Signal-Regulated Kinase (ERK1/2) is suggested to be the mediator that 
regulates the SNA response to resistin in BAT (153). Pre-treatment with an ERK1/2 inhibitor 
centrally attenuated the response elicited by resistin on BAT SNA (153). However, inhibition 
of ERK1/2 had no effects on the sympatho-excitatory effect of resistin on RSNA. 
The increase in RSNA following the administration of resistin is mediated by PI3K in the 
brain. The pre-treatment with a PI3K inhibitor attenuated the normal increases in RSNA in 
response to resistin (51). This suggests that the intracellular mechanisms by resistin on RSNA 
are mediated PI3K. This, too, is similar to the findings with leptin and suggests that resistin 
and leptin may share common central pathways with respect to their sympatho-excitatory 
responses on RSNA. Interestingly, there are no studies, to date, that have compared resistin 
and leptin in the same study. 
1.4.3 Insulin 
Insulin, a hormone synthesised and released by the beta cells of the pancreas, was first 
discovered in 1923 (154). The cognate receptor for insulin is the insulin receptor (IR), which 
is expressed in many organs, including the brain (155), liver and pancreas (156, 157). In the 
brain, insulin receptors are widely expressed in the hypothalamus; mainly in the ARC, with 
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high levels of expression in the PVN (158). The IR is densely expressed in many brain 
regions that are implicated in the control of food intake and the regulation of the autonomic 
nervous system (159, 160). As insulin is a major hormone in the control of food intake, the 
levels of this hormone are increased with body fat mass (161, 162). As body mass increases, 
insulin acts in the brain to reduce weight by decreasing food intake and increasing energy 
expenditure (163, 164). In addition to its role in metabolic function, insulin also plays a role 
in regulating cardiovascular function (165-167). 
1.4.3.1 Insulin in metabolic function 
Insulin is a hormone secreted from the pancreas mainly in response to elevated blood glucose 
levels (168). It plays an important role in regulating glucose homeostasis, as well as lipid and 
protein metabolism (169, 170). It acts on many target tissues, such as the liver and the 
muscles, to regulate metabolism. Insulin also plays a role in regulating food intake through 
the CNS (163). It is known to act through the ARC to suppress food intake and increase 
energy expenditure (171). In the ARC, insulin activates POMC neurones which have an 
effect on suppressing food intake and increasing energy expenditure through thermogenesis 
(172, 173). It also inhibits neuropeptide Y neurones in the ARC, which are known to inhibit 
the actions mediated by POMC neurones (172, 173). Therefore, in healthy conditions, as food 
intake increases, insulin is secreted to regulate glucose, suppress food intake, and increase 
energy expenditure. Studies show that mice, which lack brain insulin receptors, are generally 
obese, with impaired regulation of metabolic function (174-176). 
In overweight and obese conditions, resistance to insulin actions on metabolic function 
develops (176-178). It is also thought that insulin resistance and hyperinsulinaemia although 
caused by obesity is also a key contributor to the development of obesity (179). The 
mechanism leading to the increased resistance is not known. Dysfunction of mitochondrial 
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function, inflammation, lipotoxicity in pathways that regulate food and energy expenditure 
are believed to be contributors (180-185). 
1.4.3.2 Insulin, obesity and cardiovascular function 
In overweight and obese conditions induced by HFD, the level of plasma insulin is elevated. 
Several clinical studies link hyperinsulinaemia with elevated blood pressure (186-190). HFD 
also leads to the development of insulin resistance. As discussed earlier, insulin resistance is 
one of the characteristics of obesity and is linked to cardiovascular diseases such as 
hypertension. Thus, it is not surprising that there is a strong correlation between obesity and 
cardiovascular disease. 
1.4.3.3 Effects of insulin on heart rate and mean arterial pressure 
Insulin contributes to an elevated blood pressure and heart rate. For example, human studies 
reveal that the IV administration of insulin influences blood pressure and HR (191). This is 
also reproduced following acute ICV administration of insulin in rats (54), and acute IV 
administration in anaesthetised (192) and conscious rats (54, 193, 194). Moreover, studies 
also show that the chronic IV infusion of insulin in conscious rats also increases blood 
pressure (195, 196) and HR (197). 
The relationship of increased insulin in HFD and cardiovascular regulation has not been well 
investigated. In rabbits, HFD have been shown to increase blood pressure and insulin may 
contribute to the blood pressure elevation (41). Moreover, acute ICV administration of insulin 
in rabbits fed a HFD showed increases in MAP and HR (41). 
These findings suggest a possible link between increased insulin levels and increases in 
cardiovascular complications observed in overweight and obese conditions. 
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1.4.3.4 Role of insulin on sympathetic nerve activity 
Insulin resistance and increases in blood pressure have been linked to activation of the 
sympathetic nervous system, resulting from chronic hyperinsulinemia (110). IV infusion of 
insulin results in significant elevations of NE plasma levels in humans (191, 198), and rats 
(192, 196), suggesting that insulin elicits sympathetic activation. More directly, insulin has 
been shown to act in the brain to activate the sympathetic nerves supplying many organs (54, 
110, 199). This is discussed in the following sections. 
Lumbar sympathetic nerve activity  
Insulin is known to increase SNA to the hindlimb. The IV administration of insulin in rats 
resulted in significant increases of LSNA (200-203). This effect is mediated by actions in the 
brain since ICV administration of insulin produced a similar response (54, 204, 205). This 
has been shown in mice (53, 206) and in rats (207). 
In obese conditions, centrally administrated insulin induces increases in LSNA that are 
similar to that seen in lean controls (53, 206, 207). 
Renal sympathetic nerve activity 
In lean mice, acute ICV injection of insulin causes dose-dependent increases in RSNA (53). 
In rats, ICV insulin also increases RSNA (54). But some reports show that the effect of 
sympathetic activation on the kidney was absent upon insulin administration (200-202, 204, 
205). These variable effects in rats might be due to the different doses that were used. 
In obese animals, insulin was also found to activate RSNA. In db/db mice, the increases in 
RSNA elicited by ICV administration of insulin were similar compared to control (110). 
However, in another study it has been reported that the ICV administration of insulin in obese 
mice leads to increased RSNA, but significantly less compared to ND (53). This report 
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suggests that there might be resistance to insulin in overweight and obese conditions, and the 
resistance may be selective for metabolic function and selected cardiovascular outputs such 
as LSNA but not RSNA. 
Sympathetic nerve activity in brown adipose tissue 
BAT SNA is important for regulating metabolic function by insulin. Activation of BAT SNA 
leads to thermogenesis, increasing energy expenditure, and increasing food intake. ICV 
administration of insulin in lean mice and rats results in dose-dependent increases in BAT 
SNA (53, 54). 
The BAT SNA induced by ICV insulin in obese mice also increases but to a lesser extent 
than in lean mice (53). This suggests that the actions of insulin on BAT SNA in overweight 
and obese conditions are attenuated. 
Mechanisms meditating changes in sympathetic nerve activity by insulin 
A number of studies have investigated the cellular transduction pathways mediating the 
effects of insulin on SNA. Mitogen-activated protein kinase (MAPK) mediates the increase in 
BAT SNA induced by insulin (54). Inhibition of MAPK by PD98059 or U0126 administered 
centrally blocked the effects of insulin on BAT SNA in rats (54), but did not affect RSNA or 
LSNA (54). However, PI3K plays an important role in mediating the LSNA response to 
insulin. In lean mice, pre-treatment with LY294002, a PI3K inhibitor, in the brain attenuates 
the increases in LSNA in response to insulin (53, 54, 206). This has been seen in lean, as well 
as, obese mice (53). PI3K inhibition does not affect insulin’s ability to increase RSNA (54). 
A different mechanism mediates insulin’s RSNA effects. In homozygous and heterozygous 
MC-4R knockout mice the effects of insulin on RSNA was absent (110). Together these 
findings suggest that the activation of MC-4R is critical for the RSNA response of insulin. 
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Thus, there are distinct central pathways that mediate the sympathetic nervous system 
responses to different target organs elicited by insulin. 
1.4.4 Interaction between the hormones 
1.4.4.1 Leptin and resistin 
As discussed above, there is considerable evidence showing leptin has effects on 
cardiovascular regulation. However, little is known to date about resistin, and there are no 
studies investigating the combined effects of leptin and resistin on cardiovascular regulation. 
A few studies suggest there may be an interaction between leptin and resistin. For example, 
leptin and resistin act in the brain through the same signalling pathway involving PI3K to 
induce increases in RSNA (51, 58, 208). In a separate study in mice overexpressing resistin, 
leptin resistance was observed (209). Thus, resistin and leptin may interact to influence 
cardiovascular regulation, but this has not been examined to date. 
1.4.4.2 Leptin and insulin 
There is some evidence showing the potential for leptin and insulin to interact in the brain. 
For example, both hormones act through PI3K to induce increases in LSNA (54, 210, 211). 
More direct evidence is available from studies in the peripheral cardiovascular system, the 
combination of both hormones have additive effects on vascular tone (212). In that study, it 
was shown that both hormones combined induce a greater release of nitric oxide compared to 
each hormone alone (212). Moreover, in liver cells, insulin alone and leptin alone result in the 
activation of JAK2, STAT3/5b, and IRS-1/2. However, the combination of both leptin and 
insulin in the liver cell results in a greater activation of JAK2 and STAT5b but no change in 
STAT3, IRS-1/2 (213). Therefore, there is evidence that suggests that both insulin and leptin 
can act to enhance each other’s actions, and the interaction may be for specific 
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pathway/responses. Since kidney function is important for cardiovascular regulation, whether 
there is an interaction between leptin and insulin on RSNA should be investigated. 
1.4.4.3 Resistin and insulin 
As indicated earlier (1.4.2), resistin was first identified by its ability to induce insulin 
resistance (47). This appears to occur through the attenuation of phosphorylation of the 
insulin receptor by resistin (139). This is to our knowledge, the only example of an 
interaction between the two hormones. 
1.5 SUMMARY 
Leptin, resistin and insulin are all hormones known to be produced and released in response 
to increased food intake in normal conditions. They play important roles in metabolic 
function. In overweight and obese conditions induced by HFD, the levels of these hormones 
are increased in plasma and SNA is abnormally elevated. Increased SNA is linked to 
cardiovascular complications such as hypertension. Therefore, these hormones may be 
implicated in the elevated sympathetic activity observed in overweight and obese conditions. 
Previous work shows that leptin, resistin and insulin alone increase RSNA in ND. However, 
HFD can influence SNA responses to leptin, for example; the LSNA response is reduced but 
the RSNA response remains unaffected. In contrast, in HFD the LSNA response to insulin is 
unaffected but the RSNA response is reduced. In addition, the effect of resistin on RSNA in 
HFD is unknown. Further, the combination of (leptin + resistin), (leptin + insulin) and 
(resistin + insulin) on RSNA in both ND and HFD are unknown. This is summarised in in 
table 1.1. 
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Table 1.1 Summary effects of leptin, insulin and resistin on RSNA on a normal diet and a 
high fat diet on RSNA, and the gap that needs to be investigated. 
 
Hormones Normal Diet - RSNA High Fat Diet - RSNA 
Leptin     
Insulin   ↑ 
Resistin   ? 
Leptin + resistin ? ? 
Leptin + insulin ? ? 
Resistin + insulin ? ? 
 increase;  ↑ smaller increase;  ? Unknown  
 
1.6 AIMS 
The aims of this study are: 
1- To determine the effects on renal sympathetic nerve activity (RSNA) in rats fed a 
normal diet chow (ND) by combined administration of (i) leptin + resistin, (ii) leptin 
+ insulin, and (iii) resistin + insulin. 
2- To determine the effects of resistin on renal sympathetic nerve activity (RSNA) in rats 
fed a high fat diet (HFD). 
3- To determine whether high fat diet (HFD) influences the effects on renal sympathetic 
nerve activity (RSNA) following the combination of (i) leptin + resistin, (ii) leptin + 
insulin, and (iii) resistin + insulin. 
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2 CHAPTER 2: Materials and Methods 
2.1 INSTRUMENTS 
2.1.1 Manufacture of blood vessel cannulae  
To cannulate the femoral artery and vein for blood pressure measurement and infusion of 
drugs intravenously (respectively), cannulae were manufactured in the following way. Two 
different sizes of tubing polyvinyl chloride (PVC) were obtained. The smaller tubing 
(catalogue number 530010 – internal diameter of 0.28 mm and outer diameter of 0.61 mm; 
Biocorp, VIC, Australia) was cut to a length of approximately 7 cm and inserted to the larger 
one (catalogue number 530055- internal diameter 0.80 mm and outer diameter 1.20 mm, 
Biocorp, VIC, Australia) which was approximately 15 cm. The two tubing were connected 
using glue (Araldite ® Epoxy Resin (Selleys Pty Ltd; NSW, Australia). The glue was inserted 
between the tubing to ensure a watertight connection. A small ball of glue was made at the 
connection point between the two pieces of tubing, to allow the tying of the vessels using 
threads, to secure the catheters after they have been inserted (Figure 2.1). 
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Figure 2.1 PVC tube. 
 
A blood vessel cannula used for cannulating the femoral vessels. The small and large 
polyvinyl chloride (PVC) tubing hold together by the ball of glue. 
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2.1.2 Renal dissection instruments 
A scalpel blade was used to incise the skin, and scissors were used to blunt dissect and 
separate the skin from the muscles. Scissors were used to cut the underlying muscle. Two 
cotton tips were used to separate the fat tissue from the muscle to expose the kidney and the 
vessels innervating the kidney. Retractors were used to pull and retract the muscles, kidney 
and fat tissue aside. An operating microscope was used to identify the renal nerve. After 
identification of the nerve, it was placed onto the bared tips of two Teflon-coated silver wire 
electrodes. Paraffin oil was used to insulate the nerve electrode junction from surrounding 
tissue. An audio amplifier was used so that the renal nerve activity was audible.  
2.1.3 Manufacture of electrodes 
A Bipolar Electrode was used for sympathetic nerve activity signal recording. These Bipolar 
electrodes have two Teflon stainless steel wires (catalogue number: AGT1025, World 
Precision Instrument Inc., FL, USA). The tips of the bipolar electrodes were bent to form an 
L-shape and were stripped of the Teflon insulation for about 5 mm. To allow amplification 
the tips of the electrode were separated by approximately 4mm. The other end of the 
electrode had gold plated pins. Each electrode was covered with PVC tube to stabilized and 
protect the electrode (catalogue number 530055- internal diameter 0.80 mm and outer 
diameter 1.20 mm, Biocorp, VIC, Australia) and to reduce electrical interference (Figure 2.2). 
2.1.4 Blood pressure and heart rate instruments 
2.1.4.1 Invasive blood pressure and heart rate monitoring 
For the invasive blood pressure monitoring, a cannula was inserted into the femoral artery 
and was connected to a transducer for the recording of blood pressure using a PowerLab data 
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acquisition system (ADInstruments, NSW, Australia). The heart rate was calculated from the 
arterial pressure pulse. 
2.1.4.2 Non-invasive blood pressure and heart rate monitoring 
For the non-invasive blood pressure monitoring, a tail cuff blood pressure measurement 
system (ML125 NIBP Controller and MLT125/R Pulse Transducer/Pressure Cuff for NIBP- 
rat) was threaded over the animal’s tail and was connected to a transducer sensor. The sensor 
detects the first impulse from the tail artery once deflation occurs after being occluded by the 
cuff. 
2.1.5 Microinjection instruments  
A drill bit was used to carefully drill the dorsal surface of the skull by hand so that the dorsal 
surface of the brain was exposed for injections. ICV injections were made using glass 
micropipettes. The glass micropipettes were obtained from (Clay Adams, New Jersey, USA). 
A micropipette puller (Sutter Instrument Company, Model P-97, CA, USA) was used to make 
the fine tipped micropipette injectors. The micropipette puller was programmed so that the 
external diameter of the micropipette was approximately 60µm and the internal diameter was 
approximately 30µm when the shaft was trimmed down to approximately 12mm in length. 
2.1.6 Perfusion instruments 
Two bottles were used, one contained the phosphate buffered saline (PBS) (200-220 ml) and 
the other contains the fixative (4% paraformaldehyde) (200-220ml). Paraformaldehyde 95% 
was purchased from (Sigma Aldrich) Australia. 
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2.1.7 Brain removal instruments 
To remove the brain, a large pair of scissors was used to decapitate animals. Rongeurs were 
used to remove the neck muscles and the skull bones, and forceps were used to peel off the 
dura. A long thin spatula was used to cut the cranial nerves and remove the brain. 
2.2 HORMONES/DRUGS  
Recombinant rat resistin (lot#L16251/F, L28370,) was purchased from Sigma Aldrich 
(Australia), recombinant rat leptin (lot#AQP2411031) was purchased from Sapphire 
Biosciences (Australia), human insulin (Actrapid 100 IU/ml) was purchased from a local 
pharmacy, and saline (0.9% NaCl, Baxter) was purchased from Baxter (Australia). Urethane 
was purchased from Sigma Aldrich (Australia), and pentobarbitone (325 mg) was purchased 
from Virbac mental health (Australia). 
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Figure 2.2 Wire electrode. 
Bipolar Teflon-insulated stainless steel electrode wire insulated in a polyvinyl chloride (PVC) 
tube used for recording from the renal nerve. 
Teflon coat 
Bent bared tips 
PVC Tubing 
Gold tip plugs 
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2.3 ANIMAL HOUSE, FAT MEASUREMENTS, FOOD AND BLOOD PRESSURE 
MONITORING 
2.3.1 Animal type and weight 
From the ARC (Animal Resources Center, W.A, Australia) male Sprague-Dawley rats were 
obtained. Each animal weighed approximately between 220-240 grams upon they arrival. The 
animals were housed in temperature-controlled rooms with a 12:12 hour light / dark cycle 
(light off at 7:00 P.M.) in the Animal Facility (RMIT University, Victoria, Australia). These 
protocols comply with the Guiding Principles for Research Involving Animals and Human 
Beings and the guidelines set by the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes, 2007 (National Health and Medical Research Council of 
Australia). All experiments were approved by the Royal Melbourne Institute of Technology 
(RMIT) University Animal Ethics Committee (approval letter is attached in appendix II). 
Every attempt was made to minimise animal suffering, discomfort and reduce the number of 
animals needed to obtain reliable results. 
2.3.2 Diet 
In the experiments, rats were acclimatised for seven days prior to transfer to controlled food 
experiments. Animals were separated into two groups. One group was allowed free access to 
a ND (Fat=4.8%), and the other group was allowed free access to a HFD (SF14-004 (22% 
fat), Speciality Feeds, Glen Forrest, WA) for 8-10 weeks. Both groups were also allowed free 
access to water. Food intake was monitored by weighting the amount of food each week. 
Calorie intake was calculated from the food intake based on (14KJ/g in ND; 18KJ/g in HFD) 
of food eaten. 
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2.3.3 Systolic blood pressure monitoring  
Blood pressure was monitored using a tail cuff occlusion method, fortnightly during the 
experimental period. Firstly the animals were exposed to a heating lamp for approximately 5 
minutes and placed in a restrainer. The tail was threaded through the occlusion cuff, and the 
occlusion cuff was placed at the base of the tail. Maximum occlusion pressure was set to 250 
mmHg, and deflation was set to fifteen seconds. A blood pressure sensor was placed at the 
distal end of the cuff to monitor blood pressure. Upon deflation, the pressure at which there 
was the first appearance of a pulse was taken as the systolic pressure. 
2.3.4 Fat measurement 
To measure the percentage of body fat in animals at the end of the feeding period, an 
EchoMRI 500 body composition analyser was used. The animal was placed in a tubular 
holder and then placed inside the EchoMRI. This analyser utilises magnetic resonance to 
allow a precise body composition measurements of fat, lean, and total water mass in awake 
animals. This technique takes approximately three minutes to scan and generate values of 
body composition. 
2.4 SURGICAL PROTOCOLS  
2.4.1 Femoral vein and artery cannulation  
The femoral artery and the femoral vein were cannulated prior to microinjections. The 
cannulation of the femoral artery allows constant monitoring of blood pressure, while the 
cannulation of the femoral vein allows intravenous (IV) administration of urethane 
anaesthesia to be maintained during the length of the experiment. Initially, rats were 
anesthetized using gaseous anaesthesia (initially 5% then 2-2.5% isoflurane in O2), the right 
femoral region was shaved and swabbed with 70% alcohol. Following that, a 5-7 mm incision 
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was made through the skin over the femoral neurovascular bundle. The subcutaneous fascia 
was cleared away using blunt dissection to expose the underlying bundle. The blood vessels 
were separated by dissecting out the femoral sheath using forceps. 
The femoral vein was cannulated first. Two lengths of fine thread (silk 3/0, Dynek Pty, 
Australia) were inserted under the vessel and clamped by a haemostat. The threads were 
pulled to elevate the vessel and temporarily stop the blood flow. A fine needle (26 gauge 
needle) was inserted into the vessel, to make an access point for the cannula which was filled 
with heparinized saline (50 U/mL). Following the insertion of the needle, the cannula was 
inserted into the vessel and the needle was slowly withdrawn from the vessel. After insertion 
of the cannula the thread was tied around the cannula, and the other thread was tied around 
the ball of glue to secure the cannula in position. The femoral artery was cannulated using a 
similar procedure. Upon completion of the cannulation procedures, the incision was closed 
using stitches (silk 2/0-USP, Dynek Pty, Australia). The free end of the arterial cannula was 
connected to a transducer for recording blood pressure using a PowerLab data acquisition 
system (ADInstruments, NSW, Australia). The heart rate (HR) was calculated from the 
arterial pressure pulse. The free end of the venous cannula was used for IV infusion. General 
anaesthesia was maintained by IV infusion of urethane 0.05 ml/15 sec of a 25% solution total 
dose of (1.4-1.6 g/kg). Supplemental doses of 0.05 ml of solution were given to maintain 
deep anaesthesia if required. Anaesthesia level was determined by the absence of corneal and 
pedal pinch reflexes. 
2.4.2 Skull drilling 
Animals were placed prone, and their heads were anchored in a Stoelting stereotaxic frame, 
such that bregma and lambda were positioned on the same horizontal plane. An incision was 
made through the dorsal skin of the head. The skin and the subcutaneous tissue and 
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periosteum were cleared to expose the dorsal surface of the skull. Using a hand held drill bit, 
a hole (approximately 2 mm diameter) centred 0.7 mm caudal to bregma and 1.4 mm lateral 
from midline, was drilled into the skull to expose the dorsal surface of the brain for 
microinjections. To prevent drying of the exposed surface, the hole was covered with cotton 
wool soaked in normal saline (sodium chloride 0.9%). 
2.4.3 Renal nerve dissection  
After a flank incision, blunt dissection was used to separate the skin from muscle. Cotton tips 
were then used to separate fat tissue from muscle so that the left kidney was exposed 
retroperitoneally. With the aid of retractors, the muscle, kidney and fat tissue were pulled 
aside. Under microscopic observation, the renal nerve was identified running along the renal 
artery. We isolated the nerve without causing any damage to the nerve or blood vessels 
supplying it. Saline was used to keep the nerve and the surrounding tissue moist. The distal 
end of the nerve was dissected free of surrounding tissue. The distal end was then cut, and 
any remaining saline solution was removed. The cut end of the renal nerve was placed on the 
bipolar electrodes and covered with paraffin oil to insulate the nerve-electrode junction from 
surrounding tissue. To ensure good nerve recording, firstly we confirmed that the firing of the 
nerve signals was synchronous with the cardiac rhythm as seen in (figure 2.3). We used audio 
to hear clear bursts of the nerve activity signal. Finally, we injected a lethal dose of 
pentobarbitone (325 mg IV) at the end of the experiment to obtain the background noise 
(figure 2.3). 
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Figure 2.3 Screen capture of raw recording of renal sympathetic nerve activity 
 
Screen capture of raw recording of renal sympathetic nerve activity. (A) Renal sympathetic 
nerve activity from an anesthetized rat, horizontal bar = 2 s; vertical bar = 100 mV. (B) 
Electrical activity at the end of the experiment, after lethal dose of pentobarbitone (325 mg 
IV), and background noise is observed. 
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2.4.4 Intracerebroventricular injection  
Injections were made unilaterally using a glass micropipette (50–70 μm tip diameter) inserted 
into the lateral brain ventricle (stereotaxic coordinates: 0.7 mm caudal to bregma, 1.4 mm 
lateral to midline, and 3.7-3.9 mm ventral to the surface of the dura). Leptin (7μg/5μl), 
resistin (7μg/5μl), insulin (500 mU/5μl) and vehicle (saline 5μl) were administered ICV. The 
doses of each hormone were chosen on the basis of previous studies (113, 136). The doses 
used are larger than those observed in plasma as noted previously (48, 51, 125, 128). After 
the microinjections, the micropipette was left in place for 1 min. At the end of the 
experiment, a small amount of blue dye was microinjected using the same coordinates to 
confirm microinjection into the lateral ventricle.  
2.4.5 RSNA, MAP and HR monitoring 
The renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP) and HR were 
monitored before and for 180 minutes after hormone/saline administration at 15 minutes 
intervals. Resting levels before the ICV injections were calculated to obtain the basal levels. 
For the RSNA study, the effects of hormone/saline administration were expressed in terms of 
percentage change from baseline. RSNA was amplified using a low-noise differential 
amplifier (models ENG 187B and 133, Baker Institute, Victoria, Australia), filtered (band 
pass 100–1,000 Hz), rectified, and integrated (at 0.5 s intervals for RSNA). The signal was 
recorded using a PowerLab data acquisition system (ADInstruments, NSW, Australia). 
Background noise was determined by post-mortem measurements after the rat received a 
lethal dose of pentobarbitone (325 mg IV). RSNA was obtained by subtracting the 
(background noise) from the total activity. Basal levels were recorded as the average of three 
measurements over 15 minutes prior to hormone/saline administration. 
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2.4.6 Perfusion 
At the end of each experiment, animals were perfused. A 5-6 cm lateral incision through the 
integument and abdominal wall just beneath the rib cage was made. The diaphragm was 
incised to expose the pleural cavity. The rib cage was then cut on both sides laterally up to 
the clavicle. The sternum was then lifted, and a haemostat was used to clamp the rib cage. 
Connective tissue and the thymus were cleared to expose the heart. A 15 gauge perfusion 
needle was then passed through the left ventricle into the ascending aorta. The perfusion 
needle was secured with a clamp, and PBS (200-220 ml) was infused at a pressure of 80-100 
mmHg followed by 4% paraformaldehyde (200-220 ml) at the same pressure. 
2.4.7 Tissue collection 
To collect brains, animals were first decapitated. Muscle layers were dissected out to reveal 
the occipital bone and vertebrae. The spongy part of the occipital bone was carefully removed 
using rongeurs to reveal the cerebellum. Following the removal of the occipital bone, the 
parietal and the frontal bones were then removed using the same procedure, to reveal the 
cerebral hemispheres and brainstem. The dura mater was peeled back from the dorsal brain 
surface. Using a long thin spatula the cranial nerves were disconnected from the brain, so that 
the brain could be removed from the skull. 
The brain was placed in 4% paraformaldehyde for three hours and then into PBS (0.1M) 
containing 20% sucrose solution and stored at 4 ºC. 
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2.5 IMMUNOHISTOCHEMISTRY 
2.5.1 Sectioning of the rat brain 
Serial coronal sections (40 μm thick) of the brain were cut using a Leica CM1950 Cryostat 
(Leica Microsystems Nussloch GmbH, Nussloch, Germany) and sections were placed in 24-
well plates containing cryoprotectant. Sections were then processed immunohistochemically 
to detect Fos protein using standard immunohistochemical procedures. 
The following brain areas were examined: the hypothalamus; paraventricular nucleus (PVN), 
supraoptic nucleus (SON) and the arcuate nucleus (ARC). The median preoptic nucleus 
(MnPO) and the vascular organ of lamina terminalis (OVLT) in the lamina terminalis were 
also examined. In the midbrain, the periaqueductal grey (PAG) and finally, in the medulla, 
the nucleus of the solitary tract (NTS), rostral ventrolateral medulla (RVLM) and the raphe 
pallidus nucleus (RPA) were also examined. 
2.5.2 Immunohistochemical staining procedures 
To identify increased neuronal activation, immunohistochemistry was performed to detect the 
protein Fos, a marker for activated neurons. Sections were washed in PBS (3 times for 5 min 
duration). This was also performed between the following incubations. Endogenous 
peroxidase activity was destroyed by incubating with 0.5% H2O2. Then, sections were 
incubated in 10% normal horse serum (NHS) and 0.5% Triton X-100 to facilitate antibody 
penetration. Sections were then incubated in anti-Fos primary antibody (rabbit polyclonal 
IgG, c-Fos (K-25): sc-253, Santa Cruz Biotechnology, CA, USA; dilution: 1:5000). Sections 
were then left overnight at 4 °C. The next day sections were then incubated with (i) 
biotinylated secondary antibody (1:400, Anti-rabbit raised in goat, B8895, Sigma Aldrich, 
Australia) and subsequently (ii) Extravidin (1:400, Sigma Aldrich, Australia). Both 
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incubations were at room temperature. Then the sections were incubated in 0.05% 3,3′-
diaminobenzidine hydrochloride (DAB; Sigma Aldrich, Australia). The reaction was initiated 
by adding 5 μl of 30% hydrogen peroxide and terminated by washes with fresh PBS. Finally, 
the sections were allowed to dry and were coverslipped using Depex mounting medium. 
2.6 STATISTICAL ANALYSIS  
2.6.1 Systolic blood pressure, body weight, food intake and calorie intake 
The changes in systolic blood pressure, body weight, food intake and the average caloric 
intake per day during the feeding time were compared between the groups using two-way 
ANOVA. 
2.6.2 RSNA, MAP and HR  
The resting levels of MAP and HR before the ICV injections were compared between groups 
using one-way ANOVA. Changes in RSNA, MAP and HR were compared between groups in 
each experimental series by using two-way ANOVA with repeated measures. 
2.6.3 Fat 
The distribution of whole body fat was calculated and expressed as percentages and 
compared between groups using Student’s unpaired t-test. Similarly, epididymal fat was 
compared between groups using Student’s unpaired t-test. 
 
 
 
   41 
2.6.4 Immunohistochemistry (FOS) 
Fos-positive cell nuclei were counted unilaterally in 2 sections per brain region using Image J 
software (version 1.7.0). Numbers of Fos positive cell nuclei were compared between groups 
using one-way ANOVA. 
2.6.5 Invasive blood pressure 
The changes in the blood pressure over the feeding time were compared between groups 
using two by using two-way ANOVA. 
In all the above measures, all results are expressed as means ± SE. P<0.05 was considered to 
be statistically significant. Specific details of the statistical analysis for each study are 
provided in each specific chapter. 
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3 Chapter 3: Central Leptin And Resistin Combined Elicits Enhanced Central Effects On 
Renal Sympathetic Nerve Activity 
3.1 INTRODUCTION 
Leptin is a well known hormone released from fat tissue and acts centrally to influence 
metabolic and cardiovascular functions (18, 89, 98, 214).  It can increase renal sympathetic 
nerve activity (RSNA) and this action may make an important contribution to the abnormally 
elevated RSNA observed in obesity or overweight conditions (17, 50).  
Resistin, also a hormone released from fat tissue, has recently been shown to act centrally to 
elicit similar effects as leptin on RSNA (51). Both leptin and resistin increase RSNA through 
central mechanisms that involve phosphatidylinositol 3 kinase (PI 3-kinase) (51, 208). Thus, 
these two hormones appear to act through similar mechanisms to increase RSNA and this 
raises the question of whether combined administration of leptin and resistin could elicit 
greater increases of RSNA. This could have important implications since plasma leptin and 
resistin levels correlate with adiposity (47, 48, 131, 215), and both are elevated in obesity and 
overweight conditions. Thus, the first aim of the present study was to measure RSNA in 
response to leptin administered in the presence of resistin compared to the responses induced 
by leptin and resistin alone.  
Although there is considerable knowledge of the brain nuclei activated by leptin, there has 
not been a systematic investigation of those activated by resistin. Since similar mechanisms 
appear to be mediating the central actions of leptin and resistin, we wondered whether similar 
areas in the brain were activated and whether an enhanced effect observed when both were 
combined could be correlated with specific brain nuclei. We focused on autonomic brain 
nuclei known to influence cardiovascular function. We used the protein, Fos, as a marker of 
increased neuronal activity to quantify the number of activated neurons in each brain nucleus 
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and compared their distribution after administration of resistin with that after administration 
of leptin given alone and the combination of leptin and resistin. 
3.2 METHODS 
Please refer to Chapter 2, for a more detailed explanation on methods and materials. 
3.2.1 Ethical approval 
All the experimental protocols were performed in accordance with the Prevention of Cruelty 
to Animals Act 1986 (Australia). The procedures conform to the “Guiding Principles for 
Research Involving Animals and Human Beings” and the guidelines set out by the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013 (National 
Health and Medical Research Council of Australia) and were approved by the RMIT 
University Animal Ethics Committee (approval letter is attached in appendix II). 
3.2.2 General procedures and protocols  
Male Sprague-Dawley rats were obtained from ARC animal resources centre (W.A, 
Australia). Rats were housed at 23°C with a 12-h light/dark cycle and allowed free access to 
standard rat chow and water for 8-10 weeks. On the day of the experiment, anesthesia was 
induced using isoflurane gas (initially 5% then lowered to 2%) in O2. A catheter was inserted 
into the femoral vein, so that anesthesia could be maintained with intravenous (IV) urethane 
(1.4–1.6 g/kg initially, followed by supplemental doses of 0.05 ml of a 25% solution, as 
required). The depth of anesthesia was maintained to ensure the absence of corneal and pedal 
reflexes. The femoral artery was cannulated for monitoring arterial blood pressure. Mean 
arterial pressure (MAP) and heart rate (HR) were calculated from the arterial pressure pulse 
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using LabChart (ADInstruments, NSW, Australia). Rats were kept on a heating pad for the 
duration of the experiments to maintain body temperature at approximately 37.5 oC. 
3.2.2.1 Renal sympathetic nerve activity 
After a flank incision, the left kidney was exposed retroperitoneally. With the aid of an 
operating microscope, the renal nerve was carefully dissected free of surrounding tissue 
under mineral oil and placed onto the bared tips of two Teflon-coated silver wire electrodes. 
RSNA was amplified using a low-noise differential amplifier (models ENG 187B and 133, 
Baker Institute, Victoria, Australia), filtered (band pass 100–1,000 Hz), rectified, and 
integrated at 0.5 s intervals. The signal was recorded using a PowerLab data acquisition 
system (ADInstruments, NSW, Australia). 
3.2.2.2 Microinjections into the lateral brain ventricle (ICV) 
Each animal was placed prone, and the head was mounted in a Stoelting stereotaxic frame, 
such that bregma and lambda were positioned on the same horizontal plane. For exposure of 
the dorsal surface of the brain, a hole (2 mm diameter) centred 0.7 mm caudal to bregma and 
1.8 mm lateral to the midline, was drilled into the skull. Pressure ejection was used to make 
unilateral microinjections using a fine glass micropipette (50–70 µm tip diameter) inserted 
into the lateral brain ventricle (stereotaxic coordinates: 0.7 mm caudal to bregma, 1.8 mm 
lateral to midline, and 3.7-3.9 mm ventral to the surface of the dura). The volume injected 
was 5µl and was determined by using calibrated markings on the micropipette. After the 
microinjection, the micropipette was left in place for 1 min. At the end of the experiment a 
small amount of pontamine sky blue was microinjected using the same coordinates to 
confirm microinjection into the lateral ventricle. 
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3.2.2.3 Experimental protocols  
MAP, HR and RSNA were measured before and for three hours after administration of saline 
vehicle (n=5), leptin (7 µg; n=5), resistin (7 µg; n=4) and the combination of both resistin and 
leptin (n=6) (leptin was administered 15 minutes after resistin). The doses of each hormone 
were chosen on the basis of previous studies (113, 136). 
3.2.2.4 Immunohistochemistry for Fos 
At the end of the experiment, the animals were overdosed with pentobarbitone (325 mg IV) 
and then perfused through the heart with 200 ml of 0.1 M phosphate buffered saline (PBS, pH 
7.2), followed by 200 ml of 4% paraformaldehyde in 0.1 M PBS).  The brains were then 
carefully removed, post-fixed in the same fixative (for 3 hours) and left overnight in 0.1 M 
PBS containing 20% sucrose. 
Serial coronal sections (40 µm thick) of the brain were cut using a cryostat (Leica, CM1900, 
Germany). One in five sections was collected, placed onto gelatine-coated slides, dried for 2 
hours at room temperature and then processed immunohistochemically to detect the protein 
Fos using standard immunohistochemical procedures. In brief, endogenous peroxidase 
activity was destroyed by incubating with 0.5% H2O2 for 30 minutes. The sections were then 
incubated in 10% normal horse serum (NHS) for 60 minutes prior to 0.5% Triton X-100 (30 
minutes) to facilitate antibody penetration. The sections were then incubated in primary 
antibody raised in the rabbit against Fos (1:400, rabbit polyclonal IgG, c-Fos (K-25): sc-253, 
Santa Cruz Biotechnology, CA, USA) for 24 hours at room temperature. The sections were 
then incubated for 2 hours with biotinylated anti rabbit secondary antibody raised in goat, 
(1:400, Sigma Aldrich, Australia) and subsequently with Extravidin – peroxidase complex 
(1:400, Sigma Aldrich, Australia) for 1 hour. In between all steps the sections were washed 
three times (for 5 minutes each time) with PBS. Then the sections were incubated in 0.05% 
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3,3′-diaminobenzidine hydrochloride (DAB; Sigma Aldrich, Australia) in PBS for 10 
minutes. The reaction was initiated by adding 5 μl of 30% hydrogen peroxide and terminated 
by washes with fresh PBS. Finally, the sections were allowed to dry and were coverslipped 
with Depex. 
3.2.3 Statistical analysis  
The average resting levels of MAP and HR in the different groups of animals prior to 
hormones/saline administration were compared between groups using one-way ANOVA. The 
integrated RSNA was calculated over a period of 1-2 minutes at each time point (ie before 
and every fifteen minutes after injection) and expressed as a percentage of the resting level 
prior to the injections. Changes in MAP, HR and RSNA over time were compared between 
groups in each experimental series by using two-way ANOVA. The average of the last 30 
minutes of the observation period was used to calculate the maximum changes and these were 
compared between groups using one-way ANOVA. 
Fos-positive cell nuclei were visualised and counted unilaterally, except in the midline 
structures (raphe pallidus, dorsal raphe, median preoptic nucleus and organum vasculosum of 
the lamina terminalus), using bright field illumination at 200x magnification. At least two 
sections for each brain nucleus were examined. The average number of Fos-positive cell 
nuclei per section was calculated for each brain nucleus in each animal and comparisons 
between the groups were performed using one-way ANOVA. When an overall significant 
difference between groups was detected, comparisons were made between individual groups, 
using Holm-Sidak’s test for multiple comparisons. All results are expressed as means± sem. 
P<0.05 was considered to be statistically significant. PRISM software was used. 
 
   47 
3.3 RESULTS 
3.3.1 Effects of ICV injection of leptin and resistin on RSNA 
Intracerebroventricular (ICV) injection of leptin alone and resistin alone increased RSNA 
significantly compared to saline (control). Leptin alone increased RSNA reaching a 
maximum of approximately 75% between 2-3 hours after administration (P<0.0001 
compared to saline) (figure 3.1). Resistin increased RSNA significantly compared with saline 
and followed a similar time course to that of leptin reaching a maximum level of 
approximately 50% (P<0.0001 compared to saline). When leptin and resistin were 
administered, RSNA increased dramatically to a maximum of approximately 165%, which 
was significantly greater compared to the responses of either hormone alone (P<0.0001) 
(figure 3.1). 
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Figure 3.1 Percent changes in RSNA induced by leptin and resistin alone and in combination. 
 
Percent changes in renal sympathetic nerve activity (RSNA) from baseline levels over time 
after intracerebroventricular injection of leptin (n=5) (7μg/5μl), resistin (n=4) (7μg/5μl), 
control (saline, n=5) (5μl) and the combination of leptin and resistin (n=6). (*P<0.0001 
compared to control; #P<0.0001 compared to leptin alone or resistin alone). 
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3.3.2 Effects of ICV injection of leptin and resistin on MAP and HR. 
Leptin alone induced a small change in MAP of 4+3 mmHg by the end of the observation 
period and this was not statistically significantly different from saline control (5+2 mmHg) 
(figure 3.2).  Following resistin there was a small change in MAP by 11 + 1 mmHg, which 
followed a similar time course to that of leptin and was not statistically significantly different 
compared to saline (figure 3.2).  When leptin and resistin were administered, the response in 
MAP was not significantly different to the responses of either hormone alone or control 
(figure 3.2). 
Similarly, there was no significant difference in the responses in HR between the groups. By 
the end of the observation period, neither leptin nor resistin induced a statistically significant 
change in HR compared to saline (figure 3.2). When leptin and resistin were administered, 
the change in HR was not significantly different to the responses of either hormone alone or 
control (figure 3.2). 
The average resting MAP and HR prior to hormone/saline administration are shown in table 
3.1. One-way ANOVA analysis showed there was no significant differences between the 
groups. 
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Figure 3.2 Changes in MAP and HR induced by leptin and resistin alone and in combination. 
 
Changes in mean arterial pressure (MAP) and heart rate (HR) over time induced by the 
intracerebroventricular administration of leptin (n=5) (7μg/5μl), resistin (n=4) (7μg/5μl), 
Control (saline, n=5) (5μl) and the combination of leptin and resistin (n=6). 
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Table 3.1 Resting MAP and HR. 
 
 
Resting mean arterial pressure (MAP) and heart rate (HR) prior to intracerebroventricular 
injection of saline (n=5), leptin (n=5), resistin (n=4) and the combination of leptin and 
resistin (n=6) in anesthetised rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Saline Leptin Resistin Leptin+Resistin 
MAP (mmHg)  93.5 ± 4.1 79.7 ± 1.6  82.1 ± 3.7  90.5 ± 4.2 
HR (beats/min) 360 ± 7 336 ± 11 342 ± 10 323 ± 16 
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3.3.3 Effects of leptin and resistin, alone and in combination, on Fos-positive cell 
nuclei 
3.3.3.1 Lamina terminalis 
In the organum vasculosum of the lamina terminalis (OVLT), and in the median preoptic 
(MnPO) nucleus, the number of Fos-positive cell nuclei following leptin or resistin alone 
were not significantly different compared to control (figures 3.3 and 3.4). However, when 
leptin and resistin were administered, there was a significant increase in Fos-positive cell 
nuclei by two-fold compared to the saline control (P<0.05) (figures 3.3 and 3.4). 
3.3.3.2 Arcuate nucleus 
In the arcuate nucleus (ARC), leptin and resistin alone significantly increased the number of 
Fos-positive cell nuclei by approximately 50% and 100%, respectively, compared to control 
(figure 3.5). When leptin and resistin were administered, the increase in Fos-positive cell 
nuclei was significantly greater than in control (P<0.001) and compared to each hormone 
alone (P<0.001) (figure 3.5). 
3.3.3.3 Paraventricular and supraoptic nuclei 
In the hypothalamic paraventricular nucleus (PVN) leptin and resistin alone induced a 
significant two-fold increase in the number of Fos-positive cell nuclei compared to control 
(P<0.05) (figures 3.5 and 3.6). When leptin and resistin were administered, the increase in the 
number of Fos-positive cell nuclei was also significantly greater than control but did not 
differ from the result observed with leptin or resistin alone. In the supraoptic nucleus (SON), 
the number of Fos-positive cell nuclei following each treatment was not statistically 
significant between groups (figure 3.5). 
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Figure 3.3 Average number of Fos-positive cell nuclei in OVLT and MnPO induced by leptin 
and resistin alone and in combination. 
 
Average numbers of Fos-positive cell nuclei per section in the organum vasculosum of 
lamina terminalis (OVLT) and median preoptic nucleus (MnPO) from rats administered 
intracerebroventricular saline (control) (n=5) (5µl), leptin (n=5) (7µg/5µl), resistin (n=4) 
(7µg/5µl) and leptin combined with resistin (n=5). *P<0.05 compared to control. 
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Figure 3.4 Photomicrographs of Fos-positive cell nuclei in OVLT induced by leptin and 
resistin alone and in combination. 
 
Photomicrographs showing Fos-positive cell nuclei in the organum vasculosum of the lamina 
terminalis (OVLT) of rats following centrally administered saline (5µl; control), leptin (7µg), 
resistin (7µg) and leptin combined with resistin. Bar, 200 µm. Dashed lines outline the 
OVLT. 
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Figure 3.5 Average number of Fos-positive cell nuclei in ARC, PVN and SON induced by 
leptin and resistin alone and in combination. 
 
The average number of Fos-positive cell nuclei per section in the arcuate (ARC), 
paraventricular (PVN) and supraoptic (SON) nuclei after intracerebroventricular injection of 
saline (5µl; control), leptin (n=5) (7µg/5µl), resistin (n=4) (7µg/5µl), and leptin combined 
with resistin (n=5). *P<0.05, **P<0.01, ***P<0.001 compared to control; #P<0.001 
compared to leptin and resistin alone. 
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Figure 3.6 Photomicrographs of Fos-positive cell nuclei in PVN induced by leptin and 
resistin alone and in combination. 
 
Photomicrographs showing Fos-positive cell nuclei in paraventricular nucleus (PVN) of rats 
following centrally administered saline (5µl; control), leptin (7µg), resistin (7µg) and leptin 
combined with resistin. Bar, 200 µm. Dashed lines outline the PVN. Abbreviations, Fx, 
fornix. 
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3.3.3.4 Dorsal raphe and medulla oblongata 
In the dorsal raphe, the rostral ventrolateral medulla (RVLM), and in the nucleus tractus 
solitarius (NTS), there was no significant difference in the number of Fos-positive cell nuclei 
between the treatments (figure 3.7). In the raphe pallidus (RPA), following leptin or resistin 
alone the average number of Fos-positive cell nuclei was not significantly different from 
controls However, when leptin and resistin were administered, the number of Fos-positive 
cell nuclei was significantly reduced compared to leptin or resistin alone  (P<0.05), but was 
not significantly different from control (figure 3.7). 
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Figure 3.7 Average number of Fos-positive cell nuclei in DR, RVLM, NTS and RPA induced 
by leptin and resistin alone and in combination. 
 
Average number of Fos-positive cell nuclei per section in the dorsal raphe (DR), rostral 
ventrolateral medulla (RVLM),  nucleus tractus solitarius (NTS) and raphe pallidus (RPA) 
following saline (control) (n=5) (5µl), leptin (n=5) (7µg/5µl) resistin (n=4) (7µg/5µl) and 
leptin combined with resistin (n=5). *P<0.05 compared to leptin or resistin alone. 
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3.4 DISCUSSION 
In the present study we found that when leptin was administered ICV after resistin, there was 
a significantly greater increase in RSNA compared to the response elicited by either hormone 
alone. We also determined in a more systematic way than has been previously investigated, 
the distribution of activated neurons in the brain following resistin. Compared to saline 
control we found that resistin significantly increased the number of activated neurons in 
arcuate and hypothalamic nuclei, which was similar to leptin. We also found that in the 
OVLT, MnPO, ARC, and in the hypothalamic PVN the number of Fos-positive cell nuclei 
was increased significantly more when leptin was administered after resistin compared to 
control. However, only in the ARC was the increase in the number of activated neurons 
significantly greater than when each hormone was administered alone. In the RPA, by 
contrast, the number of Fos-positive cell nuclei was significantly reduced when leptin was 
administered after resistin compared to that observed after each hormone alone.  
In the present study, ICV leptin alone increased RSNA, as did resistin, confirming previous 
studies (99, 105). In contrast to leptin alone, the increase in RSNA induced by leptin was at 
least doubled when it was administered in the presence of resistin. This finding could have 
important implications in conditions in which leptin and resistin are elevated such as in 
obesity. In this condition RSNA is abnormally elevated (17), and since leptin is believed to 
be an important mediator of the increase in RSNA in that condition (17, 50), the presence of 
resistin could contribute to leptin’s key role in elevating RSNA in obesity. 
The mechanisms involved in the enhanced response may involve (i) activation of separate 
populations of cells; if the number of Fos positive nuclei observed following the 
administration of both hormones was the same number as each hormone alone, this would 
suggest that both hormones activate the same population of neurons. However, since more 
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cells were activated by the combination of leptin + resistin, it suggest there must be a 
population of cells that can be activated by leptin or resistin independently, and (ii) a 
population of cells that can be activated by both leptin and resistin. In the latter case, the 
intracellular transduction pathways resulting in the increased RSNA utilised by each hormone 
involves PI3K (51, 208). Thus, it is likely that both possibilities contribute to the present 
findings investigating the distribution of Fos.  
In contrast to the RSNA response, the maximum changes in MAP and HR following the 
combination of leptin and resistin, were not significantly greater than the responses observed 
when leptin or resistin were administered alone. This is somewhat surprising given the 
dramatic effect on RSNA. It is possible that anaesthesia may have an influence on the control 
of MAP and this could affect our ability to detect changes in MAP. Alternatively, the greater 
sympatho-excitatory effect is selective for the renal output and may be insufficient to elicit 
acute increases in blood pressure. Reflex responses could also contribute to attenuating an 
increase in blood pressure.  
In the present work we describe the distribution of activated neurons following resistin 
administration more extensively than has been performed in the past (125, 136, 216). We 
have also, for the first time, compared the distribution with that induced by leptin alone and 
following leptin plus resistin in combination. Resistin induced a significant increase in Fos-
positive cell nuclei in the ARC, and PVN in the hypothalamus. In other brain regions 
examined we could not detect a statistically significant difference compared to control. In the 
PVN and ARC our present data agrees with previous work (136, 216).  
In the present study, we found that leptin also significantly increased the number of Fos-
positive cell nuclei in the ARC and PVN, which agrees with previous studies that have 
investigated the distribution of activated neurons following leptin administration (217-219), 
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or studies in which leptin was microinjected into specific brain nuclei (220), or studies that 
determined the distribution of leptin receptors (221). 
We could not detect statistically significant increases in Fos-positive cell nuclei in the 
medulla oblongata following leptin administration. This is despite evidence that leptin can 
influence cardiovascular and respiratory regulation by acting within nuclei present in the 
dorsal and ventral medulla oblongata (222-224). We administered leptin into the lateral 
ventricle and it is likely that the hormone spread to more caudal brain regions including the 
medulla oblongata. Thus, it is possible that under the present conditions, we did not have the 
sensitivity to detect significant increases in Fos-positive neurons in those medullary nuclei, 
and we do not exclude actions of the hormones in the medulla. 
In contrast to leptin, there have not been studies that have microinjected resistin into brain 
nuclei nor has the receptor for resistin been identified. Thus, the distribution of activated 
neurons may provide some insight into potential sites in which resistin acts, though it must be 
recognised that the protein Fos is a marker of increased neuronal activity rather than a marker 
of neurons directly activated by resistin. 
When leptin and resistin were administered, the numbers of Fos-positive cell nuclei in the 
lamina terminalis, ARC and in the PVN were significantly greater than in controls. We found 
that only in the ARC was the increase in the number of Fos-positive cell nuclei significantly 
greater than when either hormone was administered alone. This result suggests that in the 
ARC the neurons activated by leptin include a population that is separate from the population 
activated by resistin. In contrast, a similar increase in the number of Fos-positive cell nuclei 
in the PVN was observed following each hormone alone and after leptin and resistin were 
combined, suggesting that the same population was activated by leptin and resistin. 
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The PVN receives projections from the ARC (225), so it is perhaps surprising that the 
number of Fos-positive cell nuclei was not greater in the PVN following the administration of 
leptin and resistin compared to each alone, given the dramatic increase in the ARC following 
both hormones combined. This anomaly may be explained when one considers that Fos 
protein is a marker of increased neuronal activity but not a measure of the level of increased 
activity in a neuron. Thus, in the PVN the level of neuronal activity may have increased 
dramatically when leptin and resistin were administered, without a marked increase in the 
number of neurons activated. Thus, it is possible that the same neuronal population was 
activated by the administration of leptin and resistin but to a much higher level than that 
observed after the administration of each hormone alone. Another possibility is that some 
neurons activated in the ARC may not project to the PVN. 
In contrast to all regions examined, the administration of leptin and resistin resulted in a 
significant decrease in the number of Fos-positive cell nuclei in the RPA compared to either 
hormone administered alone. This suggests a negative interaction is occurring within this 
nucleus. Since the RPA is important in the regulation of sympathetic nerve activity to brown 
adipose tissue (BAT SNA) (226), the present findings are in agreement with studies that 
show that leptin has sympatho-excitatory actions on BAT, whilst resistin has opposing 
inhibitory effects on sympathetic nerves innervating BAT (113, 136). In the present study, we 
note that there was no evidence that resistin alone reduced basal Fos production in the RPA. 
The physiological responses that may be attributed to the increase in activated neurons in the 
ARC, lamina terminalis and the PVN are unknown. The ARC is known for its involvement in 
dietary intake and cardiovascular regulation. This nucleus is well recognized as a key brain 
nucleus mediating leptin’s anorexigenic actions (227). Resistin administered acutely also 
reportedly reduces food intake (125). Thus, the present observation of enhanced neuronal 
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activity in the ARC induced by the combination of leptin and resistin could be manifested 
functionally as a change in energy balance.  
The ARC is also important in eliciting cardiovascular responses (228), and taken together 
with the present functional data on RSNA, the enhanced neuronal activity in the ARC could 
be related to the greater increase in RSNA observed when leptin and resistin were 
administered compared to the responses to each hormone alone. Further studies are needed to 
explore these possibilities. 
In a study using resistin over-expressing mice crossed with mice lacking the low density 
lipoprotein receptor, leptin levels were elevated, suggesting leptin resistance (209). Thus, as 
part of their report, the authors investigated the distribution of pSTAT3, a marker of neurons 
activated by leptin, in the ARC in vitro following leptin alone and in the presence of resistin. 
They reported that pSTAT3 levels induced by leptin were reduced by resistin (209). At first 
sight, our present data following the administration of leptin in the presence of resistin 
appears to contrast those observations. However, the results may be reconciled in that 
pSTAT3 is a marker of neurons that were activated directly by leptin, whilst the presence of 
Fos is indicative of neurons whose activity increased (not necessarily by direct effects of the 
hormones on the neuron). Nonetheless, our observations on RSNA shows that the 
combination of leptin and resistin results in a greater renal sympatho-excitatory actions than 
following either hormone alone. 
The OVLT and MnPO form part of the lamina terminalis and have been shown to have poly-
synaptic connections to sympathetic nerves innervating the kidneys (229). Those brain nuclei 
are also well known to play key roles in osmoregulation and body fluid homeostasis (229). 
Whether the marked increase in RSNA observed when leptin and resistin were combined is 
related to the greater increase in the number of Fos-positive cell nuclei in the lamina 
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terminalis awaits further investigation. Similarly, we are not aware of studies investigating 
the effects of leptin or resistin on thirst.   
Limitations of the study 
One limitation of this study is that we used anaesthetized rats. The presence of Fos is affected 
by anaesthesia, where basal levels are usually higher, than in conscious animals (230, 231). 
The results in the present study agree with that. Thus, it may be more difficult to detect 
changes from control under anesthetized conditions, so we may have underestimated the 
brain nuclei activated. Nonetheless, the fact that increases in Fos production were observed 
suggests that the areas identified are important. 
Fos is a marker of increased neuronal activity, but does not indicate the level of increased 
activity. Thus, in areas where the increase in Fos-positive cell nuclei following the 
administration of leptin and resistin were not greater than after each hormone alone, does not 
necessarily indicate there was not a greater level of activity in that brain nucleus.  
Also, in the present work we studied the effects of acute administration of the two hormones. 
We observed the responses for three hours and though clearly long enough to see changes in 
RSNA, we did not see significant effects on MAP of leptin or resistin. It has been previously 
reported that leptin administered acutely increases MAP (100). One difference between the 
present work and that study is that the increase in MAP in response to ICV leptin required 
more than three hours to be clearly observed, although RSNA was elevated earlier. Thus, it 
would also be interesting to observe the effects of leptin and resistin following chronic 
administration. This could be particularly relevant to obesity where chronically elevated 
plasma leptin levels make an important contribution to the hypertension and the elevated 
RSNA associated with obesity (232, 233). 
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Increases in RSNA can induce anti-natriuretic responses (234). In the present study we did 
not monitor changes in natriuresis or diuresis. Given the increase in RSNA we observed, one 
could expect an anti-natriuretic response. Intravenously administered leptin has natriuretic 
actions, which are mediated by peripheral mechanisms (235). Thus, central and peripheral 
actions of leptin produce opposing actions on natriuretic responses. Whether this contributes 
to the time that it takes to observe pressor responses with leptin is unknown, but it appears to 
be insufficient to prevent the chronic pressor action of leptin. 
In conclusion, the present study investigated the effects of acute central administration of 
leptin and resistin, alone and in combination, on RSNA, MAP and HR. Leptin alone and 
resistin alone increased RSNA. When leptin was administered 15 minutes after resistin, there 
was a significantly greater increase in RSNA compared to the responses to either hormone 
alone. This may be important in conditions like obesity where RSNA is abnormally elevated 
and both leptin and resistin levels are increased. The brain nuclei involved in mediating the 
enhanced increase in RSNA are not known but may involve the lamina terminalis, ARC and 
the hypothalamic PVN. 
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4 Chapter 4: Central Administration Of Insulin And Leptin Together Enhance Renal 
Sympathetic Nerve Activity And Fos Production In The Arcuate Nucleus 
4.1 INTRODUCTION 
Insulin is produced by the pancreas and released into the circulation in response to elevated 
glucose. In addition to insulin’s critical role in glucose homeostasis, there is now 
considerable interest in its role in regulating the autonomic nervous system. Insulin can 
induce increases in sympathetic outflow to cardiovascular organs, such as the kidney and 
skeletal muscle vasculature, by activating receptors within the central nervous system (53, 
58). 
Leptin is released from adipocytes and it acts centrally to influence metabolic and 
cardiovascular functions (18, 89, 98, 214).  It acts within the brain to increase sympathetic 
nerve activity to the kidney (54, 57, 99 ). The sympatho-excitatory actions of leptin to the 
kidney makes an important contribution to the abnormally elevated renal sympathetic nerve 
activity (RSNA) observed in obesity or overweight conditions (17, 50). 
Both leptin and insulin can be transported across the blood brain barrier to activate brain 
nuclei involved in cardiovascular and metabolic regulation. Pathways involving the activation 
of melanocortin 4 receptors (MC4R) is a key common mechanism mediating the increases in 
RSNA induced by leptin and insulin (110), suggesting the potential for an interaction on 
RSNA, such that increased levels of both hormones could result in an additive action on 
RSNA. Interestingly both insulin and leptin can regulate each other’s production and release, 
such that an increase in plasma levels of insulin can lead to an increase in leptin levels and 
vice versa (236, 237), which further suggests potential interactions of the two hormones. 
Thus, in order to explore the possibility that insulin and leptin interact within the brain to 
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induce greater increases in RSNA, the first aim of the present study was to compare RSNA in 
response to administration of leptin and insulin alone and in combination. 
The second aim was to explore potential sites where leptin and insulin may interact. Thus, we 
also quantified the number of activated neurons in brain regions, known to influence the 
sympathetic nervous system, and compared their distribution after central administration of 
leptin and insulin alone and both combined. 
4.2 METHODS  
Please refer to Chapter 2, for a more detailed explanation on methods and materials. 
4.2.1 Animals 
Experiments were performed to comply with the Prevention of Cruelty to Animals Act 1986 
(Australia). All experimental protocols conform with the ‘Guiding Principles for Research 
Involving Animals and Human Beings’ and the guidelines set out by the ‘Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes’, 2013 (National Health and 
Medical Research Council of Australia) and were approved by the Royal Melbourne Institute 
of Technology (RMIT) University Animal Ethics Committee (approval letter is attached in 
appendix II). Male Sprague–Dawley rats were obtained from the ARC Animal Resources 
Centre (Western Australia, Australia). Rats were housed under a 12:12 h light ⁄ dark cycle at 
23° C and allowed free access to standard rat chow and water for 8-10 weeks. 
4.2.2 General procedures and protocols 
General anaesthesia was induced using isoflurane in O2 (2–5%) on the day of the experiment 
to allow catheterisation of the femoral vein and artery. The catheter was inserted into the 
femoral vein, so that general anaesthesia could be maintained with intravenous (IV) urethane 
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(1.4–1.6 g ⁄ kg initially, followed by supplemental doses of 0.05 ml of a 25% solution if 
required). The depth of anaesthesia was maintained to ensure the absence of corneal and 
pedal pinch reflexes. The femoral artery was cannulated for arterial blood pressure 
monitoring. Mean arterial pressure (MAP) and heart rate (HR) were calculated from the 
arterial pressure pulse using LabChart (ADInstruments, Castle Hill, NSW, Australia). Rats 
were kept on a heating pad for the duration of the experiments to maintain body temperature 
at approximately 37.5 oC. 
4.2.2.1 Renal sympathetic nerve activity 
A flank incision was made to expose the left kidney retroperitoneally. Using an operating 
microscope, the renal nerve was carefully dissected free of surrounding tissue. Under mineral 
oil, the renal nerve was then cut and the proximal end was placed onto the bared tips of two 
Teflon-coated silver wire electrodes. 
The RSNA was amplified using a low-noise differential amplifier (models ENG 187B and 
133, Baker Institute, Victoria, Australia), filtered (band pass 100–1,000 Hz), rectified, and 
integrated at 0.5 s intervals. The signal was recorded using a PowerLab data acquisition 
system (ADInstruments, NSW, Australia). 
4.2.2.2 Microinjections into the lateral brain ventricle (ICV) 
Animals were placed prone, and their heads were mounted in a Stoelting stereotaxic frame, so 
that bregma and lambda were positioned on the same horizontal plane. To expose the dorsal 
surface of the brain, a hole (diameter 2 mm) centred 0.7 mm caudal and 1.4 mm lateral from 
bregma, was drilled into the skull. After the drilling procedure, the hole was covered with 
cotton wool soaked in normal saline to prevent drying of the exposed surface. A 
microinjection was made unilaterally using a fine glass micropipette (tip diameter 50–70 µm) 
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inserted into the lateral brain ventricle (stereotaxic coordinates: 0.7 mm caudal to bregma, 1.4 
mm lateral to midline, and 3.7-3.9 mm ventral to the surface of the dura). After the 
microinjection, the micropipette was left in place for 1 min. At the end of the experiment, a 
small amount of pontamine sky blue was microinjected using the same coordinates to 
confirm microinjection into the lateral ventricle. 
4.2.2.3 Experimental protocols 
MAP, HR and RSNA were measured prior to intracerebroventricular (ICV) injection of 
vehicle (saline 5 μl; n=5), leptin (7 μg in 5ul; n=5) or insulin (500 mU in 5μl; n=4) alone or in 
combination (leptin (7 μg in 5μl) was administered 15 min after insulin (500 mU in 5μl) 
(n=4)), and the responses were monitored for three hours after the last injection. Apart from 
instances in which leptin and insulin were administered in the one animal, only one injection 
per rat was performed. The doses of each hormone were chosen on the basis of previous 
studies (113, 136). The doses used are larger than those observed in plasma as noted 
previously (48, 51, 125, 128). The difference in amounts is likely to be related to the 
concentration required at the actual site of action. For saline and leptin alone, the data were 
reported in chapter 3, and used in this chapter for comparison only.  
4.2.2.4 Immunohistochemistry 
At the end of the experiment, the animals were perfused with 200 ml of 0.1M phosphate 
buffered saline (PBS, pH 7.2) transcardially, followed with 200 ml of 4% paraformaldehyde 
in 0.1 M PBS. The brains were removed carefully and post-fixed for 3-3.5 hours and then 
transferred to a solution of 20% sucrose in PBS 0.1M and stored at 4°C.   
Brains were sliced into a series of coronal sections (40 µm thick) using a cryostat (Leica, 
CM1900). Sections were collected and left in cryoprotectant until processed. One in five 
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sections were then collected and processed immunohistochemically as free floating sections 
for the detection of Fos protein. In brief, the process involved placing the sections in 0.5% 
H2O2 for 15 min to destroy endogenous peroxidase activity. This was followed by incubation 
in 10% normal horse serum (NHS) and 0.5% Triton X-100 for 60 min to facilitate antibody 
penetration. Sections were then incubated in the primary antibody raised in rabbit against Fos 
(1:5000, rabbit polyclonal IgG , c-Fos (K-25): sc-253, Santa Cruz Biotechnology, CA, USA;) 
overnight at 4°C. Sections were then incubated with biotinylated anti rabbit secondary 
antibody raised in horse, (1:400, Sigma Aldrich, Australia) for 90 minutes. This was followed 
by Extravidin–peroxidase complex (1:400, Sigma Aldrich, Australia) for 45 minutes. 
Sections were washed three times in 0.1M PBS (5 minutes each time) between each 
incubation. Sections were then placed for 10 minutes in 0.01% 3,3′-diaminobenzidine 
hydrochloride (DAB; Sigma Aldrich, Australia) + 0.02% Nickel ammonium + 0.02% Cobalt 
chloride in PBS. 5 μl of 30% hydrogen peroxide was added to begin the reaction. To end the 
reaction the sections were washed with PBS and then they were placed onto gelatine-coated 
slides and left overnight to dry, followed by coverslipping with Depex (Sigma Aldrich 
Australia) the next day. 
4.2.3 Statistical analysis 
4.2.3.1 Physiological parameters 
The resting levels of MAP and HR and RSNA before each injection were averaged from 
three 5 minute recordings taken 15-30 minutes prior to the first injection. The average levels 
were compared between groups using one-way ANOVA. The integrated RSNA, averaged 
over 1-2 minutes, was calculated at 15 minute intervals over the period of 180 min, and 
expressed as a percentage of the resting level before the hormone/saline injections. Changes 
in MAP, HR, and RSNA were compared between groups in each experimental series by 
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using two-way ANOVA. All results are expressed as the mean ± SE.  P < 0.05 was 
considered statistically significant. 
4.2.3.2 Immunohistochemistry  
Under a bright field illumination, Fos-positive cell nuclei were visualised and counted 
unilaterally, except in midline structures (organum vasculosum of the lamina terminalis 
(OVLT), medium preoptic nucleus (MnPO) and raphe pallidus (RPA)) at 200x magnification. 
At least two sections per brain nucleus were examined in each animal. The average number 
of Fos-positive cell nuclei per section was calculated for each brain region in each animal and 
comparisons between the groups were performed using one-way ANOVA.  
For both the physiological and immunohistochemical data, following the detection of an 
overall significant difference between groups, comparisons between groups administered the 
hormones and control, and between leptin+insulin combined vs leptin or insulin alone, were 
made using Holm-Sidak’s multiple comparison test. All results are expressed as means±SE. 
P<0.05 was considered to be statistically significant. PRISM software was used. 
4.3 RESULTS 
4.3.1 Effects of ICV injection of leptin and insulin on RSNA 
Following ICV injection of leptin alone RSNA increased significantly by 74+17% (P<0.0001 
compared to saline) (figure 4.1). When insulin was administered alone the increase in RSNA 
was similar to that of leptin reaching a maximum of 62+13% (P<0.0001 compared to saline) 
(figure 4.1). Following the ICV administration of the combination of leptin and insulin the 
increase in RSNA was much greater reaching a maximum response of 124+40% by 120 
minutes (P<0.0001 compared to control). The marked increase in RSNA was significantly 
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greater than that observed after each hormone was administered alone (P<0.0005) (figure 
4.1). 
4.3.2 Effects of ICV injection of leptin and insulin on MAP and HR. 
Compared to saline, there were no marked changes in MAP during the 3 hour observation 
period following leptin and insulin administered alone or combined (figure 4.2). However, 
HR increased significantly following insulin alone compared to saline (P<0.0001) (figure 
4.2). Leptin alone also significantly increased HR compared to saline (figure 4.2). When 
insulin and leptin were combined, the HR response was significantly greater than saline 
(P<0.0001), but significantly less than that of insulin alone (P<0.001) (figure 4.2). The 
response was similar to that of leptin alone. Thus, the presence of leptin attenuated insulin’s 
tachycardic actions (figure 4.2). 
Resting MAP and HR prior to the ICV injections are shown in table 4.1. No significant 
differences were detected between the groups (table 4.1). 
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Figure 4.1 Percent changes in RSNA induced by leptin and insulin alone and in combination 
in rats fed a normal diet (ND). 
 
Percent changes in renal sympathetic nerve activity (RSNA) from baseline levels over time 
after intracerebroventricular injection of leptin (n=5) (7μg/5μl), insulin (n=4) (500mU/5μl), 
saline (n=5) (5μl) and the combination of leptin and insulin (n=4). (*P<0.0001 leptin alone, 
insulin alone and both combined compared to saline; #P<0.001 insulin alone compared leptin 
and insulin combined or leptin alone. 
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Figure 4.2 Changes in MAP and HR induced by leptin and insulin alone and in combination 
in rats fed a normal diet (ND). 
 
Changes in mean arterial pressure (MAP) and heart rate (HR) over time induced by the 
intracerebroventricular administration of leptin (n=5) (7μg/5μl), insulin (n=4) (500mU/5μl), 
saline (n=5) (5μl) and the combination of leptin and insulin (n=4). (*P<0.0001 Leptin alone, 
insulin alone and both combined compared to saline; #P<0.0005 leptin and insulin combined 
compared to insulin alone). 
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Table 4.1 Resting MAP and HR. 
 
 
Resting mean arterial pressure (MAP) and heart rate (HR) prior to intracerebroventricular 
injection of saline (n=5), leptin (7ug, n=5), insulin (500mU, n=4) and the combination of 
leptin and insulin (n=4) in anesthetised rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Saline Leptin Insulin Leptin +Insulin 
MAP (mmHg)  93.5 ± 4.1 79.7 ± 1.6  88.0 ± 6.8  86.2 ± 5.6 
HR (beats/min) 360 ± 7 336 ± 11 312 ± 19 318 ± 28 
   76 
4.3.3 Effects of leptin and insulin on Fos-positive cell nuclei 
4.3.3.1 Lamina terminalis 
The numbers of Fos-positive cell nuclei in the OVLT following ICV injection of insulin 
alone were not significantly different compared to saline (control) (figure 4.3). However, in 
this brain region, leptin alone significantly increased the number of Fos-positive cell nuclei 
compared to control (100+6 vs 45+7/section, P<0.01) (figure 4.3). When leptin and insulin 
were combined the number of Fos-positive cell nuclei observed almost doubled (91+8) 
compared to control and was significantly greater than that observed following insulin alone 
(P<0.05) (figure 4.3). The response following combined leptin and insulin was similar in 
magnitude to that following leptin alone (figure 4.3).  Thus, insulin did not influence the 
response to leptin in the OVLT. 
In the MnPO, similar effects were observed; insulin alone did not significantly affect the 
number of Fos-positive cell nuclei compared to the saline control (figure 4.3) but there was a 
significant increase in Fos production after ICV leptin alone (figure 4.3). The administration 
of leptin and insulin in combination also significantly increased the number of Fos-positive 
cell nuclei compared to control (P<0.01) (figure 4.3). This increase in Fos production was 
similar to that observed after leptin alone (figure 4.3). However, the response to the 
combination of insulin and leptin was significantly greater that that observed following 
insulin alone (P<0.05) (figure 4.3). 
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Figure 4.3 Average number of Fos-positive cell nuclei in OVLT and MnPO induced by leptin 
and insulin alone and in combination in rats fed a normal diet (ND). 
 
Average numbers of Fos-positive cell nuclei per section in the organum vasculosum of 
lamina terminalis (OVLT) and median preoptic nucleus (MnPO) from rats administered 
intracerebroventricular saline (control) (n=5) (5µl), leptin (n=5) (7µg/5µl), insulin (n=4) 
(500mU/5μl), and the combination of leptin and insulin (n=4). (*P<0.01 compared to saline; 
#P<0.05 compared to insulin alone). 
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4.3.3.2 Hypothalamus 
Arcuate nucleus 
In the arcuate nucleus (ARC), leptin alone and insulin alone significantly increased the 
number of Fos-positive cell nuclei compared to control (P<0.05) (figure 4.4). The combined 
administration of leptin and insulin produced a significantly greater increase in the number of 
Fos-positive cell nuclei in the ARC compared with either hormone alone (P<0.05) (figures 
4.4 and 4.5). Thus, the response to the combined administration of insulin and leptin was 
enhanced compared to the responses of the individual hormones. 
Paraventricular and supraoptic nuclei 
In the hypothalamic paraventricular nucleus (PVN) ICV administration of leptin alone 
induced a significant increase in the number of Fos-positive cell nuclei compared to control 
(figure 4.4). However, insulin alone or the combination of leptin and insulin did not attain 
statistically significant increases compared to control (figure 4.4).  
In the supraoptic nucleus (SON), although a significant difference between the treatment 
groups was detected overall (P<0.05), the analysis of the individual comparisons between a 
treated group (ie leptin, insulin alone, or combined) compared to control did not identify a 
statistically significant difference (figure 4.4). 
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Figure 4.4 Average number of Fos-positive cell nuclei in ARC, PVN and SON induced by 
leptin and insulin alone and in combination in rats fed a normal diet (ND). 
 
The average number of Fos-positive cell nuclei per section in the arcuate (ARC), 
paraventricular (PVN) and supraoptic (SON) nuclei after intracerebroventricular injection 
saline (control) (n=5) (5µl), leptin (n=5) (7µg/5µl), insulin (n=4) (500mU/5μl), and the 
combination of leptin and insulin (n=4). (*P<0.01 compared to saline; #P<0.05 compared to 
insulin alone). 
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Figure 4.5 Photomicrographs of Fos-positive cell nuclei in ARC induced by leptin and insulin 
alone and in combination in rats fed a normal diet (ND). 
Photomicrographs showing Fos-positive cell nuclei in the arcuate nucleus of rats following 
centrally administered saline (5µl; control), leptin (7µg), insulin (500mU) and leptin 
combined with insulin. Bar=100 µm. Dashed lines outline the arcuate nucleus. The third 
ventricle is to the right of each photomicrograph. 
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4.3.3.3 Medulla oblongata 
Fos-positive cell nuclei were examined in the nucleus tractus solitarius (NTS), (RPA), and 
rostral ventrolateral medulla (RVLM) in the medulla oblongata. In the NTS and in the RPA 
there were no significant differences between groups overall. However, in the RVLM there 
was a significant difference between the groups (P<0.05). There was a significant increase in 
the number of Fos-positive cell nuclei following the administration of leptin alone (P<0.05) 
but not with insulin alone (figure 4.6). Following the combination of leptin and insulin the 
increase in Fos-positive cell nuclei was similar to that of leptin and two-fold greater than in 
control  (P<0.05 compared to control) (figure 4.6). Thus, insulin did not affect the increase 
induced by leptin in the RVLM. 
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Figure 4.6 Average number of Fos-positive cell nuclei in NTS, RPA and RVLM induced by 
leptin and insulin alone and in combination in rats fed a normal diet (ND). 
 
Average number of Fos-positive cell nuclei per section in the nucleus tractus solitarius 
(NTS), raphe pallidus (RPA) and rostral ventrolateral medulla (RVLM), following saline 
(control) (n=5) (5µl), leptin (n=5) (7µg/5µl), insulin (n=4) (500mU/5μl), and the combination 
of leptin and insulin (n=4). (*P<0.05 compared to saline). 
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4.4 DISCUSSION 
This report is the first to demonstrate that the ICV administration of leptin combined with 
insulin results in significantly greater increases in RSNA compared with either hormone 
administered alone. The sympatho-excitatory effect did not appear to be a generalised 
response since the combined administration of leptin and insulin did not result in an increased 
HR response, rather the tachycardic effects elicited by insulin alone were attenuated by the 
presence of leptin. We also investigated brain nuclei involved in autonomic regulation to 
determine whether there was a correlation with those responses and increased neuronal 
activation (detected by the presence of Fos-positive cell nuclei) when leptin and insulin were 
administered. In the regions we investigated, we found that in the ARC, OVLT, MnPO and 
RVLM the number of Fos-positive cell nuclei were significantly greater following ICV 
injection of leptin and insulin together compared to control.  However, only in the ARC was 
the increase significantly greater than insulin or leptin administered alone. 
The present work is the first to show a greater sympatho-excitatory response when leptin and 
insulin are present together compared to the responses elicited by each alone. The present 
work confirms previous studies that have shown significant increases in RSNA following the 
central administration of leptin alone or insulin alone (53, 54, 58, 99).  The significance of 
our current work is that it highlights the potential for a much greater sympatho-excitatory 
effect on RSNA in conditions in which leptin and insulin are elevated, such as metabolic 
syndrome and obesity (17, 50, 55, 56). In those conditions, RSNA is abnormally elevated and 
leptin is believed to make a critical contribution to the increase (233). Our findings suggest 
that the considerable contribution of leptin to this elevated RSNA may be, in part, due to the 
presence of increased levels of insulin. 
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In the present study we found that central administration of insulin increased heart rate, 
however, the response was prevented when leptin was present. Since the changes in HR 
elicited by central insulin are mediated by increases in sympathetic nerve activity (238), the 
inhibition of this effect when leptin was present contrasts dramatically with the observed 
effect on RSNA, and suggests that the central interactions between leptin and insulin on the 
sympathetic nervous system are complex and may reflect differences in the output to 
different organs such that effects on the renal output is an additive response whilst that to the 
heart is an antagonistic interaction. 
There was no effect on MAP following the ICV administration of leptin or insulin 
administered alone or in combination, suggesting that increases in RSNA are not sufficient to 
acutely increase MAP. The present findings are consistent with previous reports that found 
that acute ICV administration of leptin did not increase MAP over the time frame of our 
observations (99, 100). Similarly, central administration of insulin has also been reported to 
have little effect acutely on blood pressure (54, 239, 240). 
In contrast, effects on MAP following chronic systemic or central administration, for 3-10 
days, of leptin or insulin alone have been more consistent reporting significantly increased 
MAP responses (103, 107, 241). Since renal function is an important determinant in the 
regulation of chronic blood pressure, the possibility exists that if the effect of the acute 
combination of leptin and insulin on RSNA could be reproduced with chronic infusions, then 
increases in MAP in conditions in which both hormones are chronically elevated may occur, 
but this awaits further investigation. 
Previous work on interactions between leptin and insulin has focussed on metabolic 
functions, with little investigation into interactions on cardiovascular function. In particular, 
there is a distinct gap investigating an interaction on the cardiovascular responses arising 
from leptin and insulin acting within the brain, despite the fact that the central mechanisms 
   85 
that mediate the increase in RSNA induced by leptin or insulin alone have a common 
pathway that involves the activation of MC4 receptors (110). This strongly suggests that an 
interaction is likely, and the present study now provides evidence to support a central 
interaction on RSNA. 
The central interaction of insulin and leptin may not be restricted to the renal output. 
Evidence indicates that increases in lumbar sympathetic nerve activity induced by centrally 
administered insulin involves phosphatidylinositol 3 kinase (PI3K) as is the case with leptin, 
whilst the increase in sympathetic nerve activity to brown adipose tissue (BAT SNA) induced 
by leptin or insulin involves activation of Extracellular Signal-Regulated Kinase (ERK1/2) 
(54). Thus, an interaction between leptin and insulin influencing at least three sympathetic 
outputs is a distinct possibility. 
In the present study we investigated the distribution of activated neurons using the protein 
marker, Fos, in cell nuclei in brain regions known for their contribution to cardiovascular 
regulation. Only in the ARC was the number of activated neurons significantly greater 
following the combination of leptin and insulin than the increase seen after either hormone 
alone. This result is in agreement with reports that show leptin and insulin act within the 
ARC to increase sympathetic nerve activity (SNA) (53, 54, 100, 110, 203, 227, 242-244). 
Thus, the activation of neurons in the ARC would be in accord with the increase in RSNA 
induced by leptin or insulin. The greater number of activated neurons in the ARC after the 
administration of leptin and insulin in combination correlates with the greater increase in 
RSNA compared to each hormone alone that we observed. 
We found a significant increase in Fos-positive cell nuclei in the lamina terminalis (OVLT, 
MnPO), hypothalamic PVN and in the RVLM following leptin administration. We did not 
detect a statistically significant increase following insulin in those same regions.  Although, 
the PVN and RVLM are believed to be involved in mediating the sympatho-excitatory effects 
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of hyperinsulinemia, microinjections of insulin directly into those brain nuclei did not induce 
an increased SNA suggesting there is no direct activation of insulin receptors in those brain 
nuclei (200, 201, 245). Since we found that insulin alone increased RSNA, it was perhaps, 
surprising that we did not detect an increase in Fos in those regions. Whether the type of 
anesthesia used (eg urethane in this study and alpha chloralose in those mentioned above) 
contributes to this anomaly is unknown. We also acknowledge that the numbers of animals 
may be a limitation to detect small changes. In contrast, no anomaly appears to exist with 
leptin since it significantly increased Fos production in the PVN and RVLM. Other factors 
that could contribute to the greater basal Fos may include duration of the stimulus and the 
surgical intervention that has occurred. Additionally, it should be noted that subtle influences 
or changes in the nuclei that affect sympathetic outflow may not be easily visualised by the 
use of the immunohistochemical detection of Fos. 
In the OVLT, MnPO, and RVLM the combined administration of leptin and insulin 
significantly increased Fos-positive cell nuclei but the effects were similar to leptin alone. 
Thus, in those brain nuclei, the results suggest that the increase in Fos-positive nuclei were 
due primarily to leptin and that that there was no evidence of an additive interaction between 
leptin and insulin in those brain nuclei. These findings contrast with the observations we 
made in the ARC, suggesting that interactions between leptin and insulin in the brain may 
occur in selective brain nuclei. 
4.5 SUMMARY AND CONCLUSIONS 
In summary, following ICV administration of leptin and insulin together there was a 
significantly greater increase in RSNA than either hormone alone. Insulin alone increased HR 
significantly but this was prevented by the presence of leptin. MAP was not significantly 
different between groups. Of the brain regions examined, only in the ARC did the 
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combination of leptin and insulin together increase the number of Fos-positive cell nuclei 
significantly more than the increases following leptin or insulin alone. In contrast, in the 
lamina terminalis and RVLM, leptin and insulin combined increased Fos-positive cell nuclei 
to levels similar to leptin alone. The results suggest that where leptin and insulin are elevated, 
there may be greater increases in RSNA. This may contribute to cardiovascular 
complications. The ARC may be a common site of cardiovascular integration for leptin and 
insulin. 
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5 Chapter 5: Effects Of Central Administration Of Resistin On Renal Sympathetic Nerve 
Activity In Rats Fed A High Fat Diet; A Comparison With Leptin 
5.1 INTRODUCTION 
Resistin is a member of the resistin-like molecule (RELM) hormone family and is so named 
because of its ability to induce insulin resistance. In obese and diabetic humans and rats 
resistin levels in plasma are elevated (47, 48, 131). Resistin levels correlate with an increased 
risk of hypertension and major cardiovascular events like stroke and myocardial infarction 
(246-249). Resistin acts in the brain, and mRNA for resistin has been detected in several 
brain nuclei of rodents suggesting there is also endogenous production of resistin in the brain 
(250, 251). 
Resistin acts centrally to increase renal sympathetic nerve activity (RSNA) (51). These 
effects are similar to those observed with another well-known adipokine, leptin (99, 100). 
Both leptin and resistin increase RSNA through central mechanisms that involve 
phosphatidylinositol 3 kinase (PI3K) (51, 58, 208), and this may explain why the combined 
administration of leptin and resistin elicits greater increases of RSNA than either alone. 
Increased dietary intake of fat leads to increased adipose tissue and increased circulating 
levels of leptin and resistin (47, 48, 131). Cerebrospinal fluid levels of leptin in humans 
correlate with circulating levels of leptin and adiposity (252). Cerebrospinal fluid levels of 
resistin also correlate with circulating levels in males but not females and this has been 
interpreted as an impairment in the uptake process of resistin into the central nervous system 
(CNS) in obese women (124). Diets high in fat lead to a reduction in the sensitivity to the 
anorexigenic actions of leptin (253, 254). However, the sympatho-excitatory action of leptin 
on RSNA is not affected by high fat diets (HFD). This has led to the view of a selective 
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resistance to leptin (18, 79, 87, 255) and could be a key mechanism contributing to obesity 
induced hypertension (17, 20).  
Since resistin, like leptin, increases RSNA, we investigated whether a HFD could influence 
the sympatho-excitatory effects induced by resistin. Furthermore, we also explored whether a 
HFD would influence the increase in RSNA induced by the combination of resistin and 
leptin, since the combined effect of resistin and leptin in normal chow fed (ND) rats results in 
significantly greater sympatho-excitatory actions on RSNA, as shown in chapter 3 (256). 
5.2 METHODS 
Please refer to Chapter 2, for a more detailed explanation on methods and materials. 
5.2.1 Ethical approval 
All the experimental protocols were performed in accordance with the Prevention of Cruelty 
to Animals Act 1986 (Australia). The procedures conform to the ‘Guiding Principles for 
Research Involving Animals and Human Beings’ and the guidelines set out by the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013 (National 
Health and Medical Research Council of Australia) and were approved by the RMIT 
University Animal Ethics Committee (approval letter is attached in appendix II). 
5.2.2 General procedures and protocols 
Male Sprague–Dawley rats were obtained from ARC animal resources centre (Canning Vale, 
WA, Australia). Upon arrival rats were acclimatised for one week, before a controlled 
feeding period began. Rats were divided into two groups, where one group was exposed to a 
ND (4.8% fat) and the other to a HFD (SF14-004 (22% fat), Speciality Feeds, Glen Forrest, 
WA). Rats were housed in groups of two at 23°C with a 12 h–12 h light–dark cycle and 
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allowed free access to rat chow and water. The feeding period lasted for 8-10 weeks, and 
body weight, food intake, and caloric intake were monitored weekly. In addition, systolic 
blood pressure was monitored fortnightly during the feeding period, using a non-invasive tail 
cuff occlusion method. At the end of the feeding period, the percent whole body fat was 
determined using an EchoMRI 500 (Houston Texas, USA) in a sample of animals of each 
dietary treatment. 
On the day of the experiment, anaesthesia was induced using isoflurane (2-5% in O2, 
followed by femoral artery and vein cannulation as previously described in chapter 2 (256). 
The femoral vein was cannulated so that anaesthesia could be maintained with intravenous 
(IV) of urethane (1.4–1.6 g/kg; IV with supplemental doses of 0.05 ml of a 25% solution, if 
required). The depth of anaesthesia was maintained to ensure the absence of corneal and 
pedal reflexes. The femoral artery was cannulated to monitor mean arterial pressure (MAP) 
and heart rate (HR) was determined from the arterial pressure pulse using LabChart 
(ADInstruments, NSW, Australia). Rats were kept on a heating pad for the duration of the 
experiments to maintain body temperature at approximately 37.5 oC. The rats were not fasted 
prior to the experimental day. 
5.2.2.1 Renal sympathetic nerve activity 
After a flank incision, the left kidney was exposed retroperitoneally and dissected clear of 
surrounding tissue, placed onto the hooked, bared-ends of Teflon-coated bipolar silver 
electrodes and insulated from the surrounding tissue by covering them with paraffin oil as 
previously described in chapter 2 (51, 256). RSNA was amplified using a low-noise 
differential amplifier (models ENG 187B and 133, Baker Institute, Victoria, Australia), 
filtered (band pass 100–1,000 Hz), rectified, and integrated at 0.5 s intervals. The signals was 
recorded using a PowerLab data acquisition system (ADInstruments, NSW, Australia) (256). 
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The background electrical noise levels were determined post mortem and subtracted from the 
nerve activity obtained in the anesthetised rat. 
5.2.2.2 Microinjections into the lateral brain ventricle 
Rats were placed prone, with the head mounted in a stereotaxic frame, such that bregma and 
lambda were positioned on the same horizontal plane. To expose the dorsal surface of the 
brain, a hole (2 mm diameter), centred 0.7 mm caudal to bregma and 1.4 mm lateral to the 
mid-line, was drilled into the skull. Unilateral microinjections (5 µl) were made using a fine 
glass micropipette (50–70µm tip diameter) inserted into the lateral brain ventricle (stereotaxic 
co-ordinates: 0.7 mm caudal to bregma, 1.4 mm lateral to the mid-line and 3.7–3.9 mm 
ventral to the surface of the dura). The micropipette was left in place for 1 min, after the 
microinjection. At the end of the experiment, a small amount of Pontamine Sky Blue was 
microinjected using the same co-ordinates to confirm microinjection into the lateral ventricle. 
5.2.2.3 Experimental protocols 
The MAP, HR and RSNA were measured before and for 180 min after administration of 
saline vehicle (n = 5; 5µl), leptin (7 µg in 5µl; n = 4), resistin (7 µg in 5µl; n = 5) and the 
combination of both resistin and leptin (n = 6; leptin was administered 15 min after resistin). 
The doses of each hormone were chosen on the basis of previous studies (113, 136, 256). At 
the end of the experiment, the epididymal fat was removed and weighed. 
5.2.3 Statistical analysis 
5.2.3.1 Within high fat diet 
The average resting levels of MAP, HR and integrated RSNA prior to hormone 
administration were compared between groups using one-way ANOVA. The integrated 
RSNA, averaged over 1-2 minutes, was calculated at 15 minute intervals over the period of 
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180 min, and expressed as a percentage of the resting level before the intracerebral injections. 
Changes in MAP, HR and RSNA over time following hormone/saline administration were 
compared between groups by using two-way ANOVA. When an overall significant 
difference between groups was detected, comparisons were made between individual groups, 
using Holm-Sidak’s test for multiple comparisons. The maximum responses in each variable 
were calculated by averaging the last 30 min of the observation period in each rat. 
5.2.3.2 Comparisons between high fat and normal chow diets 
The changes in RSNA, MAP and HR over time following leptin alone, resistin alone and the 
combination of leptin and resistin were compared between HFD and ND using two-way 
ANOVA. Data for the ND fed rats used for this comparison has been reported previously in 
chapter 3 (256). The calculated maximum responses were compared between the dietary 
groups using Student’s unpaired t-test. 
The body weight, average food intake, average caloric intake, and systolic blood pressure 
during the feeding period were compared between dietary groups using two-way ANOVA. 
Systolic blood pressure was measured via indirect tail cuff plethysmography. Due to a 
technical issue, systolic blood pressure was recorded before and for 6 weeks after the start of 
feeding. The percentage of whole body fat and the epididymal fat were compared between 
the dietary groups using Student’s unpaired t-test. 
All results are expressed as means ± SEM. A value of P<0.05 was considered to be 
statistically significant. PRISM software was used (GraphPad San Diego, California, USA). 
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5.3 RESULTS 
5.3.1 Rats fed a high fat diet 
5.3.1.1 Effect on RSNA 
The intracerebroventricular (ICV) injection of resistin alone and leptin alone increased RSNA 
significantly compared with the saline control (P<0.0001, figure 5.1). Resistin alone 
increased RSNA, which followed a similar time course to that of leptin and reached a 
maximum of 62±4%. Leptin alone increased RSNA, to a maximum of 71±16%. When 
resistin and leptin were combined, there was a significantly greater increase in RSNA 
(maximum change of 195±41%) than that observed following resistin or leptin alone 
(P<0.0001) (figure 5.1). 
5.3.1.2 Effect on MAP and HR 
There were no significant differences in the changes in MAP between the groups over the 
duration of observation (figure 5.2).  
There was a significant difference between the groups in the HR responses over time 
(P<0.0001). However, by the end of the observation period, neither resistin nor leptin alone 
or both in combination induced a statistically significant change in HR compared to saline 
(figure 5.2).  
 The resting levels of both MAP and HR prior to hormone administration did not show any 
significant differences between groups (see figure 5.6). 
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Figure 5.1 Percent change in RSNA induced by leptin and resistin alone and in combination 
in rats fed a high fat diet (HFD). 
 
Percent change in renal sympathetic nerve activity (RSNA) from baseline levels over time in 
rats fed a high fat diet (HFD) after intracerebroventricular injection of leptin (n=4) (7μg/5μl), 
resistin (n=5) (7μg/5μl), control (saline, n=5) (5μl) and the combination of leptin and resistin 
(n=6). *P<0.0001 leptin alone, resistin alone and the combination of both hormones 
compared to saline; #P<0.0001 combination of leptin and resistin compared to leptin alone or 
resistin alone. 
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Figure 5.2 Change in MAP and HR induced by leptin and resistin alone and in combination 
in rats fed a high fat diet (HFD). 
 
Change in mean arterial pressure (MAP) and heart rate (HR) over time in rats fed a high fat 
diet (HFD) induced by the intracerebroventricular administration of leptin (n=4) (7μg/5μl), 
resistin (n=5) (7μg/5μl), control (saline, n=5) (5μl) and the combination of leptin and resistin 
(n=6). *P<0.0001 leptin alone, resistin alone and the combination of both hormones 
compared to saline. 
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5.3.2 Comparison of responses to leptin and resistin in rats fed high fat vs normal 
chow diets 
5.3.2.1 RSNA  
There was a no statistically significant difference overall in the RSNA response elicited by 
resistin over time or in the maximum response in rats fed a HFD compared to the response in 
rats fed a ND (figure 5.3). Similarly, the RSNA response to leptin was not significantly 
different between rats fed the different diets (figure 5.3). 
When resistin and leptin were combined, the increase in RSNA appeared to be slower in 
onset in the HFD rats and there was an overall statistically significant difference between 
groups (P<0.005 two-way ANOVA) (figure 5.3), but comparisons between individual time 
points failed to show a significant difference at any time point. Despite the apparent slower 
start, the maximum increase in RSNA was not significantly different by the end of the 
observation period from the response seen in rats fed ND (figure 5.3). 
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Figure 5.3 RSNA response following leptin and resistin alone and in combination in rats fed a 
high fat diet (HFD) or normal diet (ND). 
 
Renal sympathetic nerve activity (RSNA) responses between rats fed a normal chow (ND) 
and a high fat diet (HFD), elicited by intracerebroventricularly administered resistin (n=4 
ND, n=5 HFD) (7 μg/5 μl), leptin (n=5 ND, n=4 HFD) (7μg/5μl), the combination of leptin 
and resistin (n=6 ND and HFD). Left panels show changes in RSNA over time; Right panels 
show the average maximum change in RSNA. *P<0.005 compared to ND. 
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5.3.2.2 MAP and HR  
There was a statistically significant difference detected in the change in MAP induced by 
resistin alone over time between rats fed the HFD and ND (P<0.05) (figure 5.4). The 
maximum change in MAP in the rats fed a HFD was significantly less than that seen in the 
ND fed rats (P<0.005) (figure 5.4). However, there were no significant differences in the 
changes on MAP over time or in the maximum responses in rats fed the HFD compared to 
the ND when leptin was administered alone or when leptin and resistin were combined 
(figure 5.4). 
The HR response over time and the maximum change in HR induced by resistin alone in the 
HFD rats were significantly smaller than that observed in the rats fed a ND (figure 5.5). The 
HR response over time induced by leptin alone was also significantly smaller in the HFD rats 
(P<0.05), however, the maximum change in HR was not significantly different between the 
rats fed the different diets (figure 5.5). When leptin and resistin were combined there were no 
significant differences in the HR responses over time, or in the maximum HR changes 
observed in rats fed the two different diets (figure 5.5). 
Basal MAP and HR prior to hormone administration in rats fed a HFD were not significantly 
different from those observed in rats fed a ND (figure 5.6). 
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Figure 5.4 MAP response following leptin and resistin alone and in combination in rats fed a 
high fat diet (HFD) or normal diet (ND). 
 
Comparison of the mean arterial pressure (MAP) responses between rats fed a normal chow 
(ND) and a high fat diet (HFD), elicited by intracerebroventricularly administered resistin 
(n=4 ND, n=5 HFD) (7 μg/5 μl), leptin (n=5 ND, n=4 HFD) (7μg/5μl), the combination of 
leptin and resistin (n=6 ND and HFD). Left panels show changes in MAP over time; Right 
panels show the average maximum change in MAP. *P<0.005 compared to ND. 
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Figure 5.5 HR response following leptin and resistin alone and in combination in rats fed a 
high fat diet (HFD) or normal diet (ND). 
 
Comparison of the heart rate (HR) responses between rats fed a normal chow (ND) and a 
high fat diet (HFD), elicited by intracerebroventricularly administered resistin (n=4 ND, n=5 
HFD) (7 μg/5 μl), leptin (n=5 ND, n=4 HFD) (7μg/5μl), the combination of leptin and resistin 
(n=6 ND and HFD). Left panels show changes in HR over time; Right panels show the 
average maximum change in HR. #P< 0.0001 compared to ND; *P < 0.05 compared ND. 
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Figure 5.6 Basal level of MAP and HR in rats fed a high fat diet (HFD) or normal diet (ND) 
prior to hormone administration. 
 
Basal levels of mean arterial pressure (MAP) and heart rate (HR) in rats fed normal chow diet 
(ND; open bar) and high fat diet (HFD; black bar) before intracerebroventricular 
administration of resistin (n=4 ND, n=5 HFD) (7 μg/5 μl), leptin (n=5 ND, n=4 HFD) 
(7μg/5μl) and the combination of both hormones (n=6 ND and HFD) (7 μg/5 μl). 
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5.3.2.3 Comparison of systolic BP and metabolic parameters in rats fed high fat vs normal 
chow diets 
Systolic blood pressure changes during the feeding period 
Systolic blood pressure in the HFD fed rats rose over time but this was not sustained and was 
not statistically different from that observed in rats fed the ND (figure 5.7). 
Metabolic parameters 
The percent whole body fat mass was approximately 40% greater in the rats fed the HFD 
compared to the rats fed a ND (P<0.05) (figure 5.8). Similarly, epididymal fat was 
significantly greater, by approximately 50%, in the HFD compared to the ND fed group 
(P<0.005) (figure 5.8). 
Body weight, food and caloric intake 
Over time, body weight increased in both the HFD and ND fed groups of rats, with a small 
but significantly greater increase seen in the HFD group (P<0.005) (figure 5.9). This occurred 
despite the significantly lower average daily food intake in the HFD rats (P<0.0001) (figure 
5.9). However, the average daily caloric intake was significantly greater in rats fed the HFD 
(P<0.0001) (figure 5.9). 
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Figure 5.7 Systolic blood pressure changes over time. 
 
Systolic blood pressure changes over time in rats fed a normal chow diet (ND) (n=11) and 
high fat diet (HFD) (n=11). 
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Figure 5.8 Fat distribution in rats fed a high fat diet (HFD) or normal diet (ND). 
 
Upper panel: Effect of high fat diet (HFD (n=13) on the whole body fat mass compared to 
rats fed a normal chow diet (ND) (n=12). *P<0.05.  Lower panel:  Effect of high fat diet 
(HFD (n=16) on the epididymal fat mass compared to rats fed a normal chow diet (ND) 
(n=15). #P<0.005 between groups. 
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Figure 5.9 Effects of body weight, food intake and calorie intake over time. 
 
Effect of high fat diet (HFD; n=17-19) on the body weight, food intake per day and average 
calorie intake per day over time compared to rats fed a normal chow diet (ND) (n=13). 
#P<0.005, *P<0.0001 between groups. 
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5.4 DISCUSSION 
The key findings of the present work are that in the HFD rats, resistin and leptin (alone and in 
combination) act in the brain to induce significant increases in RSNA and that combining 
resistin and leptin elicited significantly greater effects than either hormone alone. Further, 
MAP and HR responses induced by resistin, leptin and both combined were not significantly 
different from the control group. Comparing the responses induced by the hormones in the 
HFD rats to those observed in the rats fed ND showed that the HFD had no effect on the 
maximum increases in RSNA. The results suggest that with high fat feeding, the increase in 
RSNA induced by resistin is not reduced. 
The increase in RSNA induced by centrally administered resistin in the HFD rats was 
significantly greater than in the control group, and was similar to that observed in rats fed a 
ND. Thus, the sensitivity to the sympatho-excitatory effects on RSNA induced by resistin 
was not affected by high fat feeding. This was similar to our observations with leptin. Our 
findings with leptin are in agreement with studies in the rodent that show high fat feeding 
does not reduce the sympatho-excitatory RSNA responses to leptin (18, 58, 257). In the 
rabbit, however, the RSNA response to leptin was greater following high fat feeding (17).  
Since the effects of leptin on sympathetic outputs like lumbar and brown adipose tissue 
(BAT) are reduced by HFD, as is the effect on dietary intake (18, 58), the evidence indicates 
that the RSNA response elicited by leptin may be selectively resistant to the actions of high 
fat feeding (79, 87, 255, 258).  Our present findings suggest that the excitatory effects of 
resistin on RSNA are not influenced by HFD and this could be interpreted to mean that 
resistin’s actions on RSNA are also resistant to the desensitising effects of HFD. The 
influence of HFD on responses in lumbar sympathetic nerve activity (LSNA) and brown 
adipose tissue sympathetic nerve activity (BAT SNA) elicited by resistin have not been 
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investigated to date. In rats fed ND resistin increases LSNA which also occurs with leptin 
(99, 136). In contrast, resistin reduces BAT SNA, and hence thermogenesis, which is 
opposite to leptin (113, 136). This could contribute to the conclusion that resistin induced 
resistance to leptin’s thermogenic effects (209). 
In the HFD rats, the combined administration of leptin and resistin produced a greater 
response in RSNA compared to each hormone alone. A similar effect was observed in ND 
fed rats (256). The magnitude of the enhancement was similar by the end of the observation 
period irrespective of the dietary regime. This also suggests that the sensitivity of the RSNA 
response elicited by resistin and leptin is not markedly affected by HFD. 
There did appear to be a slower onset in the RSNA response elicited by the combination of 
resistin and leptin in the HFD fed rats compared to ND fed rats. This suggests there may be 
some influence of diet on the development of the sympatho-excitatory RSNA response, 
though not on the magnitude of the response. The influence of the HFD, on the development 
of the RSNA response, however, was not observed when either hormone was administered 
alone. The renal sympatho-excitatory effects of resistin and leptin involves  PI3K (51, 208). 
Thus the present findings suggest that this mechanism is not influenced by high fat feeding. 
This contrasts to the anorexigenic effect of leptin where the evidence suggests that 
intracellular transduction pathways involving SOCs3, PTP1B and PKA mediate the 
decreased sensitivity to leptin receptor activation seen with HFD (259-261). 
It has been argued that changes in receptor densities with different diets could also influence 
sensitivity to leptin and resistin.  The receptor for resistin has not been identified, hence, there 
are no studies investigating receptor distribution for resistin. Leptin receptors have been 
investigated and the receptor density in the brain does not appear to change markedly with 
high fat feeding (262). However, the receptor protein levels were reduced with high fat 
feeding suggesting this could contribute to the decreased sensitivity observed to some of the 
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actions of leptin (262). The increased circulating levels of leptin and resistin that are 
associated high fat feeding and increased adiposity would therefore be less effective if the 
receptor protein levels are reduced. However, the present study suggests this does not appear 
to influence the RSNA response elicited by centrally administered leptin or resistin. 
The MAP responses to resistin alone, leptin alone and both combined were not significantly 
different compared to control in the HFD fed rats. Compared to the responses seen in the rats 
fed a ND, the maximum changes in MAP induced by leptin alone, or leptin combined with 
resistin were not significantly different to those in the HFD fed rats. Interestingly, the 
maximum change in MAP elicited by resistin alone was lower in the HFD fed group 
compared to the ND fed group. 
Previous studies with leptin in HFD rodents have shown that the acute effect of leptin on 
MAP was not influenced by the diet (18). In rabbits fed a HFD, however, acute ICV 
administration of leptin resulted in an increased MAP and this response was similar to that 
seen in rabbits fed a ND (17, 102). In longer-term studies, the MAP response induced by a 
chronic infusion of leptin was not increased by HFD in rodents (18). 
To date there are no reports of the effects of chronic long-term infusion of resistin on blood 
pressure. Thus, it remains to be determined whether chronic infusion of resistin can increase 
blood pressure and whether the response can be influenced by a HFD. 
In the HFD rats the HR responses to each hormone alone or in combination were not 
significantly different compared to control. The comparisons of the maximum changes in HR 
seen in the rats fed a ND or a HFD showed there were no significant differences following 
leptin alone or in combination with resistin. However, the maximum change in HR with 
resistin alone was lower in the HFD fed group, as was seen with MAP. The physiological 
relevance of the differences in the HR and MAP responses between the diets following 
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resistin alone are difficult to interpret. We suspect the differences are probably a statistical 
anomaly since the changes in MAP and HR elicited by resistin alone within the HFD group 
were not significantly different from the saline control. 
In the present study, systolic blood pressure over the duration of the dietary feeding regime 
was not significantly elevated by the HFD compared to ND feeding. This is similar to 
previous studies using Wistar rats fed a HFD for 10-20 weeks which did not show an 
elevation in blood pressure (263). Sprague-Dawley rats may segregate into obese prone and 
obese resistant rats but only those prone to obesity are reported to have increased blood 
pressure following 8-10 weeks of a HFD (264), or 13 weeks of a HFD (19). In the present 
study we used Sprague Dawley rats fed for up to 10 weeks and we suspect the difference may 
be that we did not see any evidence of segregation. We did see a small but significantly 
greater increase in body weight over time in the HFD fed rats though this was smaller than 
that observed in the obese prone rats previously reported (19, 264). By contrast we have 
observed that Long-Evans rats fed a western diet (60% fat) had a small but significant 
increase in blood pressure compared to ND fed rats (265). In mice it has been found that 
when they are fed a HFD for 10 weeks they become obese with an elevated blood pressure 
when measured directly using radiotelemetric probes (18). In the present study we measured 
blood pressure via tail cuff plethysmography which will not detect small differences 
accurately. In rabbits, high fat feeding for only 4 weeks appears sufficient to induce 
hypertension (17). Thus, elevations in blood pressure in rodents fed HFD seems to be 
variable and may depend on various factors including the strain, amount of fat in the diet and 
the duration of feeding, whereas rabbits appear to be particularly susceptible to obesity-
induced hypertension. 
There was a small increase in body weight over time with the HFD. This was due to the 
increased intake of calories by rats on the HFD, even though the rats reduced their average 
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daily intake of the HFD. We did not observe any segregation of rats into obese-sensitive or 
obese-resistant groupings in this study, although this has been reported (19). Nonetheless, 
there was a clear redistribution of body fat in rats fed the HFD such that there was a 40% 
increase in percent body fat and a larger increase in the amount of epididymal fat present. 
Thus, although we did not observe an overt obesity in the HFD fed rats, a clear redistribution 
of body fat was seen. 
Perspective views 
In HFD fed rats ICV administration of resistin or leptin alone increased RSNA. The 
combination of both hormones resulted in a greater increase in RSNA compared to each 
hormone alone. The responses were similar in magnitude to those observed in rats fed a ND, 
suggesting that feeding a HFD sufficient to markedly alter visceral fat distribution, but elicit 
only a small, but statistically significant, increase in body weight, does not diminish the 
greater increase in RSNA. Thus, we find no evidence of a reduced sensitivity of the RSNA 
response elicited by centrally administered resistin. Furthermore, as both hormones act via 
PI3K to increase RSNA, these results may suggest that the stimulatory effect is not 
desensitized following a HFD feeding. 
Furthermore, our study suggests that in conditions in which both resistin and leptin are 
elevated, such as in obesity and diabetes, there may be greater sympatho-excitatory actions 
on RSNA, compared to that elicited by each hormone alone. This may contribute to the long-
term cardiovascular complications associated with those conditions, however, this requires 
further investigation. 
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6 Chapter 6: Central Administration Of Insulin Combined With Resistin Reduced Renal 
Sympathetic Nerve Activity In Rats Fed A Normal diet Or A High Fat Diet  
6.1 INTRODUCTION 
Insulin is a hormone produced by the pancreas, in response to elevated blood glucose (110). 
Insulin is released into the circulation and can cross the blood-brain barrier. Insulin receptors 
are widely distributed in the central nervous system (CNS) (158, 266, 267), and their 
activation by insulin can influence body weight control, glucose homeostasis and sympathetic 
nerve activity to the kidney, hindlimb and brown adipose tissues (53, 54, 85, 110, 163, 200, 
202, 203, 268-271). 
Resistin is an adipokine, which is produced by adipose tissue, and has been shown to play a 
role in promoting insulin resistance (151, 272, 273). Recent studies have demonstrated that 
resistin acts in the brain to elicit increases in sympathetic nerve activity to the kidney (RSNA) 
and hindlimb (51, 136), which is similar to central actions of insulin. By contrast, resistin 
reduces sympathetic nerve activity to brown adipose tissue (BAT SNA) (136). 
The sympatho-excitatory effects of resistin and leptin are similar to the sympatho-excitatory 
actions of centrally administered leptin (51, 73, 100, 256). Furthermore, we have recently 
found that the combined administration of resistin and leptin into the lateral brain ventricle 
induced a greater increase in RSNA than that induced by either hormone alone, as has been 
shown in chapter 3 (256). Similarly, in a more recent study, we have found that the combined 
administration of leptin and insulin produced a greater increase in RSNA compared to either 
leptin or insulin alone, as has been shown in chapter 4 (274). Therefore, one could 
hypothesise that the combined administration of insulin and resistin may also produce a 
greater increase in RSNA. However, resistin is known to induce resistance to insulin’s 
metabolic action (151, 272, 273). Thus, in this study we investigated the effect of combined 
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administration of insulin and resistin on RSNA in rats fed a normal chow diet (ND). This 
interaction may be important in conditions in which both hormones are elevated, for example 
in conditions of high adiposity. 
Consumption of high fat diets (HFD) is known to reduce the dietary effects of leptin, as well 
as insulin (53, 78, 79, 176, 177). The increase in RSNA induced by leptin, however, remains 
unaffected by HFD. Similarly, the excitatory action of resistin on RSNA is not affected by a 
HFD (275).  The RSNA responses to insulin, however, are controversial, and have only been 
performed in two studies in mice (53, 110). Thus, insulin effects may be influenced by HFD 
and this could impact on interactions with resistin. The effects of insulin in HFD has not been 
examined in rats previously. 
Therefore, the main aims of the present study were to investigate (i) the central effects of 
insulin in rats fed a HFD, and (ii) the central effects of combined administration of resistin 
and insulin on RSNA in rats fed a ND, and whether HFD was able to influence the responses. 
6.2 METHODS 
Please refer to Chapter 2, for a more detailed explanation on methods and materials. 
6.2.1 Ethical approval 
All the experimental protocols were performed in accordance with the Prevention of Cruelty 
to Animals Act 1986 (Australia). The procedures conform to the ‘Guiding Principles for 
Research Involving Animals and Human Beings’, and the guidelines set out by the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013 (National 
Health and Medical Research Council of Australia) and were approved by the RMIT 
University Animal Ethics Committee (approval letter is attached in appendix II). 
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6.2.2 General procedures and protocols 
Male Sprague-Dawley rats were obtained from ARC animal resources (Canning Vale, WA, 
Australia). Rats were acclimatised for 7 days after arrival and were housed at 23°C with a 12 
h light–dark cycle. The rats were allowed free access to water and food; one group were fed 
with ND (4.8% fat), and the others were fed a HFD (SF14-004 (22% fat), Speciality Feeds, 
Glen Forrest, WA) for 8-10 weeks. Body weight, food intake and caloric intake were 
monitored weekly. Using a non-invasive tail cuff occlusion method, systolic blood pressure 
was monitored fortnightly during the feeding period. The percent whole body fat was 
determined at the end of the feeding period, using an EchoMRI 500 (Houston Texas, USA) in 
a sample of animals of each dietary treatment. 
On the day of the experiments, rats were anaesthetized using isoflurane gas (2-5% in O2). The 
femoral vein and artery were cannulated as previously described in chapter 2 (Habeeballah 
2016). The femoral vein was cannulated to maintain anaesthesia using intravenous (IV) 
urethane (1.4-1.6 g/kg, supplemented with 0.05 ml of a 25% solution if required). The depth 
of anaesthesia was maintained to ensure the absence of corneal and pedal reflexes. The 
femoral artery was cannulated for monitoring the arterial pressure. The mean arterial pressure 
(MAP) and heart rate (HR) were determined from the arterial pressure pulse using LabChart 
(ADInstruments, NSW, Australia). To maintain body temperature at approximately 37.5 oC 
rats were kept on a heating pad during the experiments. 
6.2.2.1 Renal sympathetic nerve activity 
After a flank incision, the left kidney was exposed retroperitoneally as previously described 
in chapter 2 (51, 256). RSNA was amplified using a low-noise differential amplifier (models 
ENG 187B and 133, Baker Institute, Victoria, Australia), filtered (band pass 100–1,000 Hz), 
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rectified, and integrated at 0.5 s intervals. The signal was recorded using a PowerLab data 
acquisition system (ADInstruments, NSW, Australia) (256). 
6.2.2.2 Microinjections into the lateral brain ventricle 
Using a stereotaxic frame, rats were placed prone, and bregma and lambda were positioned 
on the same horizontal plane. A hole (2 mm diameter), centered 0.7 mm caudal to bregma 
and 1.4 mm lateral to the mid-line, was drilled into the skull, to expose the dorsal surface of 
the brain. Unilateral microinjections (5 µl) were made using a fine glass micropipette (50–
70µm tip diameter) inserted into the lateral brain ventricle (stereotaxic co-ordinates: 0.7 mm 
caudal to bregma, 1.4 mm lateral to the mid-line and 3.7–3.9 mm ventral to the surface of the 
dura). The micropipette was left in place for 1 min, after the microinjection. At the end of the 
experiment, a small amount of Pontamine Sky Blue was microinjected using the same 
coordinates to confirm microinjection into the lateral ventricle. 
6.2.2.3 Experimental protocols 
MAP, HR and RSNA were measured before and for 180 min after administration of saline 
(control) (n=5 HFD and ND), resistin (7 µg; n=4 ND, n=5 HFD), insulin (500 mU; n=6 ND, 
n=5 HFD) and the combination of both resistin and insulin (n=7 ND, n=5 HFD; insulin was 
administered 15 min after resistin). The doses of each hormone were chosen on the basis of 
previous studies (113, 136, 256). At the end of the experiment, the epididymal fat was 
removed and weighed. 
6.2.3 Statistical analysis 
6.2.3.1 Within diet 
The average resting levels of MAP and HR before hormone administration were compared 
between groups using one-way ANOVA. The integrated RSNA averaged over 1-2 minutes, 
   115 
was calculated at 15-minute intervals over the period of 180 min and expressed as a 
percentage of the resting level before the injections. Changes in MAP, HR and RSNA over 
time following hormone/saline administration were compared between groups by using two-
way ANOVA. When an overall significant difference between groups was detected, 
comparisons were made between individual groups, using Holm-Sidak’s test for multiple 
comparisons. 
6.2.3.2 Comparisons between high fat and normal chow diets 
The changes in RSNA, MAP and HR over time following resistin alone, insulin alone and the 
combination of insulin and resistin were compared between HFD and ND using two-way 
ANOVA. Data for resistin alone and saline (control) in ND and HFD has been reported by 
our lab previously in chapter 3 and 5 (256, 275) and were used in this study for comparison. 
For the insulin alone, the data in the ND rats includes data previously published and reported 
in chapter 4 (274), but we have increased the amount of data by adding N=2 more rats. 
The body weight, average food intake, average caloric intake, and systolic blood pressure 
during the feeding period were compared between dietary groups using two-way ANOVA. 
Systolic blood pressure was measured via indirect tail cuff plethysmography. Due to a 
technical issue, systolic blood pressure was recorded before and for 6 weeks after the start of 
feeding. The percentage of whole body fat and the epididymal fat were compared between 
the dietary groups using Student’s unpaired t-test. 
All results are expressed as means ± SEM. A value of P<0.05 was considered to be 
statistically significant. PRISM software was used for statistical analysis and graphical 
representation (GraphPad San Diego, California, USA). 
 
   116 
6.3 RESULTS 
6.3.1 Rats fed a normal diet 
6.3.1.1 Effect on RSNA 
When insulin and resistin were given in combination, there was no increase in RSNA and this 
was not significantly different from the saline (control) group (figure 6.1). However, this 
response was significantly different compared to insulin or resistin alone (P<0.0001) (figure 
6.1). Insulin alone increased RSNA significantly by 81±28% (P<0.0001 compared to saline). 
Similarly, RSNA increased significantly following the ICV injection of resistin alone (Figure 
6.1). 
6.3.1.2 Effect on MAP and HR 
There was an overall statistically significant difference between groups in the change in MAP 
(P<0.0001) (figure 6.2). Following the administration of resistin and insulin in combination, 
there was no significant differences in the change in MAP compared to either hormone alone. 
However, there was a small but statistically significant difference from the saline (control) 
group (P=0.0001) (figure 6.2). ICV administration of insulin alone had no significant effect 
on MAP compared to saline (figure 6.2). 
There was also an overall significant difference in the HR responses between the groups 
(P<0.0001) (figure 6.2). Compared to saline, insulin alone and the combination of insulin 
with resistin significantly increased HR (P<0.0001) (figure 6.2). 
The resting levels of both MAP and HR before hormone administration were not significantly 
different between groups. 
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Figure 6.1 Percent change in RSNA induced by resistin and insulin alone and in combination 
in rats fed a normal diet (ND). 
 
Percent changes in renal sympathetic nerve activity (RSNA) from baseline levels over time in 
rats fed a normal chow diet (ND) after intracerebroventricular injection of insulin (n=6) (500 
mU/5μl), resistin (n=4) (7μg/5μl), control (saline, n=5) (5μl) and the combination of resistin 
and insulin (n=7). *P<0.0001 insulin alone and resistin alone compared to saline; #P<0.0001 
combination of resistin and insulin compared to resistin alone or insulin alone. 
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Figure 6.2 Change in MAP and HR induced by resistin and insulin alone and in combination 
in rats fed a normal diet (ND). 
 
Change in mean arterial pressure (MAP) and heart rate (HR) over time in rats fed a normal 
chow diet (ND) induced by the intracerebroventricular administration of insulin (n=6) (500 
mU/5μl), resistin (n=4) (7μg/5μl), control (saline, n=5) (5μl) and the combination of resistin 
and insulin (n=7). *P<0.0001 between groups. 
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6.3.2 Rats fed a high fat diet 
6.3.2.1 Effect on RSNA 
In rats fed a HFD, there was a significant increase in RSNA following intracerebroventricular 
(ICV) administration of insulin alone compared to saline (P<0.0001) and reached a maximum 
of 46±16% (figure 6.3). Similarly, resistin alone increased RSNA significantly over time and 
reached a maximum of 64±4% (P<0.0001 compared to saline). 
When resistin and insulin were administered in combination, RSNA fell by over 35% and 
was significantly different compared to saline (P<0.0001) (figure 6.3). The reduction in 
RSNA following the combined administration of resistin and insulin was significantly 
different from the increases observed following resistin alone (P<0.0001) and insulin alone 
(P<0.0001) (figure 6.3). 
6.3.2.2 Effect on MAP and HR 
There was an overall significant difference in the MAP response between groups (P<0.01) 
(figure 6.4). The comparison between individuals showed that only the response to insulin 
was significantly different compared to saline (P<0.005) (figure 6.4). 
In the HR response, the comparison between individual groups showed that resistin alone 
(P<0.0001), insulin alone (P<0.05) and the combination (P<0.05) were significantly different 
from saline. 
When resistin and insulin were combined the HR response was significantly different from 
resistin alone and insulin alone (P<0.0001). 
The resting levels of both MAP and HR prior to hormone administration did not show any 
significant differences between groups. 
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Figure 6.3 Percent changes in RSNA induced by resistin and insulin alone and in 
combination in rats fed a high fat diet (HFD). 
 
Percent change in renal sympathetic nerve activity (RSNA) from baseline levels over time in 
rats fed a high fat diet (HFD) after intracerebroventricular injection of insulin (n=5) (500 
mU/5μl), resistin (n=5) (7μg/5μl), control (saline, n=5) (5μl) and the combination of resistin 
and insulin (n=5). *P<0.0001 insulin alone and resistin alone compared to saline; #P<0.0001 
combination of resistin and insulin compared to resistin alone or insulin alone or saline. 
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Figure 6.4 Change in MAP and HR induced by resistin and insulin alone and in combination 
in rats fed a high fat diet (HFD). 
 
Change in mean arterial pressure (MAP) and heart rate (HR) over time in rats fed a high fat 
diet (HFD) induced by the intracerebroventricular administration of insulin (n=5) (500 
mU/5μl), resistin (n=5) (7μg/5μl), control (saline, n=5) (5μl) and the combination of resistin 
and insulin (n=5). *P<0.01; #P<0.0001 between groups. 
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6.3.3 Comparison of responses to resistin and insulin in rats fed high fat vs normal 
chow diets 
6.3.3.1 RSNA 
In rats fed a HFD the increase in RSNA following insulin was significantly less compared to 
rats fed a ND (P<0.01) (figure 6.5). However, the response to resistin was not significantly 
different between dietary groups (figure 6.5). 
When both hormones were combined, there was a statistically significant difference in the 
RSNA response between the diets. In the HFD RSNA fell markedly compared to the ND 
(P<0.01) (figure 6.5). 
6.3.3.2 MAP and HR 
The response to MAP over time induced by insulin alone or in combination with resistin was 
not significantly different between the diets (figure 6.6). However, the response to resistin 
was significantly less in rats fed a HFD compared to ND (P<0.001) (figure 6.6). 
The HR response to insulin was significantly less in rats fed a HFD compared to rats fed a 
ND (P<0.0001) (figure 6.7). Similarly, resistin alone also induced a smaller HR response in 
the HFD group (P<0.0001) (figure 6.7). When resistin and insulin were administered in 
combination, there was an increase in the HR that was not significantly different between the 
rats fed a HFD or ND (figure 6.7). 
The basal level of the MAP and HR prior the hormones administration were not significantly 
different between the dietary groups (see figure 6.8). 
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Figure 6.5 RSNA response following resistin and insulin alone and in combination in rats fed 
a high fat diet (HFD) or normal diet (ND). 
 
Renal sympathetic nerve activity (RSNA) responses over time between rats fed a normal 
chow (ND) and a high fat diet (HFD), elicited by intracerebroventricularly administered 
resistin (n=4 ND, n=5 HFD) (7 μg/5 μl), insulin (n=6 ND, n=5 HFD) (500 mU/5μl) and the 
combination of resistin and insulin (n=7 ND, n=5 HFD). *P<0.01 compared to ND. 
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Figure 6.6 MAP response following resistin and insulin alone and in combination in rats fed a 
high fat diet (HFD) or normal diet (ND). 
 
Mean arterial pressure (MAP) responses over time between rats fed a normal chow (ND) and 
a high fat diet (HFD), induced by intracerebroventricularly administered of resistin (n=4 ND, 
n=5 HFD) (7 μg/5 μl), insulin (n=6 ND, n=5 HFD) (500 mU/5μl) and the combination of 
resistin and insulin (n=7 ND, n=5 HFD). *P<0.05 compared to ND. 
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Figure 6.7 HR response following resistin and insulin alone and in combination in rats fed a 
high fat diet (HFD) or normal diet (ND). 
 
Heart rate (HR) responses over time between rats fed a normal chow (ND) and a high fat diet 
(HFD), induced by intracerebroventricularly administered of resistin (n=4 ND, n=5 HFD) (7 
μg/5 μl), insulin (n=6 ND, n=5 HFD) (500 mU/5μl) and the combination of resistin and 
insulin (n=7 ND, n=5 HFD). *P<0.0001 compared to ND. 
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Figure 6.8 Basal level of MAP and HR in rats fed a high fat diet (HFD) or normal diet (ND) 
prior to hormone administration. 
 
Basal levels of mean arterial pressure (MAP) and heart rate (HR) in rats fed normal chow diet 
(ND; open bar) and high fat diet (HFD; black bar) before intracerebroventricular 
administration of resistin (n=4 ND, n=5 HFD) (7 μg/5 μl), insulin (n=6 ND, n=5 HFD) 
(500mU/5μl) and the combination of both hormones (n=7 ND, n=5 HFD). 
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6.3.3.3 Comparison of systolic BP and metabolic parameters in rats fed high fat vs normal 
chow diets 
Systolic blood pressure changes during the feeding period 
There was no significant difference observed in the systolic blood pressure over time between 
rats fed a HFD and rats fed a ND (figure 6.9). 
Metabolic parameters 
There was a significant increase in the percent of whole body fat mass in rats fed a HFD 
(P<0.005) (figure 6.10). Similarly, epididymal fat was increased significantly in the HFD 
groups (P<0.05) (figure 6.10). 
Body weight, food and caloric intake 
In rats fed HFD, body weight increased over time and it was slightly but significantly greater 
compared to ND (P<0.005) (figure 6.11). Caloric intake was also greater in the HFD group 
(P<0.0001), but the average daily food intake in the HFD fed rats was significantly lower 
than in the ND group (P<0.0001) (figure 6.11). 
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Figure 6.9 Systolic blood pressure changes over time. 
 
Systolic blood pressure over time in rats fed a normal chow diet (ND) (n=11) and high fat 
diet (HFD) (n=14). 
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Figure 6.10 Fat distribution in rats fed a high fat diet (HFD) or normal diet (ND). 
 
Upper panel: Effect of high fat diet (HFD) (n=12) on the whole body fat mass compared to 
rats fed a normal chow diet (ND) (n=10). *P<0.005 between groups.  
Lower panel: Effect of high fat diet (HFD) (n=14) on the epididymal fat mass compared to 
rats fed a normal chow diet (ND) (n=12). #P<0.05 between groups. 
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Figure 6.11 Effects of body weight, food intake and calorie intake over time. 
 
Effect of high fat diet (HFD; n=18-19) on the body weight, food intake per day and average 
calorie intake per day over time compared to rats fed a normal chow diet (ND) (n=18). 
#P<0.005, *P<0.0001 between groups. 
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6.4 DISCUSSION 
In this study, the key findings are that in rats fed a ND, the combination of resistin and insulin 
did not increase RSNA which was significantly different to the sympatho-excitatory effects 
seen with resistin alone or insulin alone. In rats fed the HFD, insulin induced a significant 
increase in RSNA, but this was smaller than the increase observed in the group fed a ND. 
Surprisingly in the HFD group, when resistin and insulin were combined, RSNA did not 
increase but, rather, fell by 35%. 
In the present study, we show for the first time that in rats fed a HFD insulin acts centrally to 
induce increases in RSNA. However, the increase was significantly less than that observed in 
rats fed a ND. This result is in agreement with reports in agouti obese mice compared to lean 
mice (53). However, in another report insulin increased RSNA in ob/ob obese mice and the 
response was not less than in control lean mice (110). Thus, the present study would lend 
weight to the suggestion that HFD decreased the sensitivity to insulin to elicit an increase in 
RSNA. 
In rats fed ND, both resistin and insulin alone elevate RSNA, therefore, when combined we 
expected a greater effect than each alone, as we observed previously with the combination of 
resistin and leptin and also the combination of leptin and insulin (see chapter 3 and 4) (256, 
274). Surprisingly, our present results show that the combination of resistin and insulin did 
not increase RSNA in ND rats, and in the HFD rats RSNA fell significantly. Thus, the results 
suggest a centrally-mediated resistance to the sympatho-excitatory effects when resistin and 
insulin are combined and this negative interaction is exacerbated by HFD. 
Previous studies show that resistin induces resistance to the metabolic functions of insulin 
(151, 272, 273). Our present results suggest that this may also occur for RSNA. However, 
such an explanation is unlikely to fully explain the marked reduction in RSNA observed in 
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the HFD, and the absence of any increase in ND following the combined administration of 
resistin and insulin. There are differences in the central mechanisms used by the two 
hormones to elicit an increase in RSNA. Resistin utilises phosphatidylinositol 3 kinase 
(PI3K) whereas it is not involved in the RSNA response to insulin (51, 54). Whether such 
differences contribute to our present observations is unknown. Clearly, the interaction 
between resistin and insulin needs further exploration, as this may be important in conditions 
in which both hormones are elevated. 
The dramatic central interaction between resistin and insulin that resulted in the marked 
decrease in RSNA in the HFD in the present study differs markedly to our previous findings 
of resistin combined with leptin.  In that study, a greater increase in RSNA than that induced 
by either hormone alone was observed (see chapter 5) (275). Thus, two opposing effects 
occur involving interactions with resistin despite the fact that insulin, leptin and resistin alone 
induce increases in RSNA (17, 18, 51, 53, 58, 87, 110). The mechanisms contributing to the 
complex interactions of these important hormones needs to be investigated in future studies. 
In the present study, we did not see a significant difference between the HFD and ND in the 
MAP responses to insulin alone or combined with resistin. This contrasts with the RSNA 
responses. This suggests that in the HFD, the marked reduction in RSNA after acute 
administration of insulin combined with resistin was not sufficient to induce a fall in MAP, or 
compensatory mechanisms come into play. 
In HFD, the HR response induced by insulin was significantly less than in the ND, and this 
difference between diets was also seen with resistin. However, when insulin and resistin were 
combined, there was no significant difference in the HR responses between the diets. This is 
a very different interaction compared to that seen with the RSNA response, suggesting that 
there is little evidence for resistin inducing resistance to insulin in the HR response. This 
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suggests that resistance to insulin may not be a generalised effect of resistin but may target 
selected outputs. 
Body weight increased over time and the increase in HFD was significantly greater than in 
the ND. This was associated with a greater increase in caloric intake in the HFD animals but 
a lower total food intake compared to the ND rats. In the HFD there was a clear redistribution 
of body fat. There was no difference in systolic blood pressure over the feeding period 
between the groups. These findings are in agreement with our previous observations in 
chapter 5 (275). These metabolic changes highlight that marked interactions between insulin 
and resistin occur within the brain even in the absence of overt obesity. 
Perspective 
In rats fed a HFD centrally administered insulin or resistin alone increased RSNA, but the 
response to insulin was significantly attenuated compared to ND. No such attenuation was 
seen with resistin. Surprisingly, combining insulin and resistin did not increase RSNA in ND, 
and resulted in a marked fall in RSNA in HFD rats. 
In obese and overweight conditions both insulin and resistin levels are elevated. The results 
of the present study, suggest that this may not be detrimental to RSNA and therefore to renal 
function. However, in overweight/obese conditions RSNA is abnormally elevated, and it 
contributes to the associated hypertension (35, 41). This suggests that the mechanisms 
responsible for increasing RSNA overcome the inhibitory action of the combination of 
resistin and insulin. In a previous study we found that resistin combined with leptin resulted 
in a greater increase in RSNA than that produced by each hormone alone (see chapter 5) 
(275). Since leptin is also elevated in obesity, it is conceivable that the presence of resistin 
acts in combination with leptin to contribute to the sympatho-excitatory RSNA actions and 
this overcomes the sympatho-inhibitory response of the combination of resistin and insulin. 
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7 Chapter 7: Central Administration Of Insulin Combined With Leptin Reduces Renal 
Sympathetic Nerve Activity In Rats Fed A High Fat Diet 
7.1 INTRODUCTION 
Insulin is a hormone produced by the pancreas (154, 276). It plays an important role in 
glucose homeostasis and autonomic nervous system regulation by acting through its 
receptors, which are widely distributed throughout the central nervous system (CNS) (163, 
169, 170, 277, 278). Insulin acts within the brain to induce increases in sympathetic nerve 
activity to the kidney, hindlimb and brown adipose tissue (53, 54, 202, 203, 205). 
Leptin is a hormone produced by adipose tissue. It is well known to play important roles in 
metabolic regulation and cardiovascular function (63, 68-71). Leptin acts centrally to increase 
the sympathetic nerve activity to kidney, hindlimb and brown adipose tissue (50, 73, 99, 100, 
105). Thus, leptin and insulin have similar effects on these sympathetic nervous system 
outputs. 
Indeed, leptin and insulin increase the sympathetic drive to the kidney through a common 
pathway within the brain mediated by activation of melanocortin 4 receptors (MC-4R) (110). 
This suggests these hormones may augment each other’s actions on renal sympathetic nerve 
activity (RSNA). In fact, we have found previously, in chapter 4, that combined central 
administration of leptin and insulin induced greater increases in RSNA, than each hormone 
alone, in rats fed a normal diet (ND) (274). This augmented sympatho-excitatory response in 
RSNA, following the combination of leptin and insulin, may be implicated in the abnormally 
elevated RSNA seen in overweight /obesity, conditions in which leptin and insulin are 
elevated (79, 85-87, 161, 162). 
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High fat diet (HFD) significantly attenuates the metabolic action of leptin and insulin (78, 79, 
178). However, leptin’s effect on RSNA is not attenuated by HFD (17, 53, 79, 110), whilst 
the effects of HFD on the RSNA response to insulin is still controversial (53, 110). 
Thus, HFD can induce resistance to the metabolic actions of leptin and insulin but with the 
RSNA response only the actions of insulin may be reduced by HFD. 
Therefore, in this study, we investigated whether HFD induced resistance to the effects of 
leptin and insulin combined on RSNA. 
7.2 METHODS 
Please refer to Chapter 2, for a more detailed explanation on methods and materials. 
7.2.1 Ethical approval 
Experiments were performed to comply with the Prevention of Cruelty to Animals Act 1986 
(Australia). All experimental protocols conform with the ‘Guiding Principles for Research 
Involving Animals and Human Beings’ and the guidelines set out by the ‘Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes’, 2013 (National Health and 
Medical Research Council of Australia) and were approved by the Royal Melbourne Institute 
of Technology (RMIT) University Animal Ethics Committee (approval letter is attached in 
appendix II). Male Sprague–Dawley rats were obtained from the ARC Animal Resources 
Centre (Western Australia, Australia). Rats were housed under a 12:12 h light ⁄ dark cycle at 
23° C and allowed free access to standard rat chow and water. 
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7.2.2 General procedures and protocols 
Upon arrival, rats were acclimatised for one week then were allowed free access to food and 
water. One group was exposed to ND (4.8% fat) and the other to a HFD (SF14-004 (22% fat), 
Speciality Feeds, Glen Forrest, WA) for 8-10 weeks. On the day of experiments, isoflurane 
gas (2-5%) in O2 was used to induce general anaesthesia. The femoral vein was cannulated 
for intravenous (IV) infusion of urethane (1.4–1.6 g/kg; IV with supplemental doses of 0.05 
ml of a 25% solution, if required) to maintain anaesthesia. In addition, the femoral artery was 
cannulated to measure and record blood pressure and heart rate. Mean arterial pressure 
(MAP) and heart rate (HR) were calculated from the arterial pressure pulse using LabChart 
(ADInstruments, Castle Hill, NSW, Australia). Rats were kept on a heating pad for the 
duration of the experiments to maintain body temperature at approximately 37.5oC. 
The left kidney was exposed using a retroperitoneal approach. The renal nerve was identified 
and carefully dissected free of surrounding tissue. Under mineral oil, the renal nerve was cut 
and the proximal end was placed onto the bared tips of two Teflon-coated silver wire 
electrodes as previously described in chapter 2. 
7.2.2.1 Microinjections into the lateral brain ventricle 
Animals were placed prone, and their heads were mounted in a Stoelting stereotaxic frame, so 
that bregma and lambda were positioned on the same horizontal plane. A hole (diameter 2 
mm) was drilled into the skull (centred 0.7 mm caudal and 1.4 mm lateral from bregma). The 
microinjections was made unilaterally using a fine glass micropipette (tip diameter 50–70 
µm) inserted into the lateral brain ventricle (stereotaxic coordinates: 0.7 mm caudal to 
bregma, 1.4 mm lateral to midline, and 3.7-3.9 mm ventral to the surface of the dura). After 
the microinjection, the micropipette was left in place for 1 min. At the end of the experiment, 
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a small amount of pontamine sky blue was microinjected using the same coordinates to 
confirm microinjection into the lateral ventricle. 
7.2.2.2 Experimental protocols 
In these experiments, MAP, HR and RSNA were recorded before and for 3 hours after the 
intracerebroventricular (ICV) administration of control (saline; 5 μl) (n=5), leptin (7 µg; 5 μl) 
(n=4), insulin (7 µg; 500 mU) (n=5) and the combination of both insulin and leptin (n=5) (5 
μl of each hormone; leptin was administered 15 min after insulin). The resting level was 
recorded for approximately 15 minutes before the ICV administration of hormone/saline. The 
variables were calculated every 15 minutes prior to and for 3 hours after the injection. 
7.2.3 Statistical analysis 
7.2.3.1 Within high fat diet 
Resting levels of MAP and HR before hormone administration were compared between 
groups using one-way ANOVA. The integrated RSNA was calculated and averaged over 1-2 
minutes at each time point over the period of 180 minutes, and expressed as a percentage of 
the resting level before the ICV injections. Changes in MAP, HR and RSNA over time 
following ICV administration were compared between groups by using two-way ANOVA. 
When an overall significant difference between groups was detected, comparisons were made 
between individual groups, using Holm-Sidak’s test for multiple comparisons. 
7.2.3.2 Comparisons between high fat and normal chow diets 
The changes in RSNA, MAP and HR over time following the hormones were compared 
between dietary groups using two-way ANOVA. For comparisons shown in the figures using 
the hormones alone and with animals fed a ND we have used data from previous chapters 
(256, 274, 275). All results are expressed as means ± SEM. A value of P<0.05 was 
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considered to be statistically significant. PRISM software was used (GraphPad San Diego, 
California, USA). 
7.3 RESULTS 
7.3.1 Rats fed a high fat diet 
7.3.1.1 Effect on RSNA 
ICV administration of leptin and insulin combined resulted in a reduction in the RSNA so 
that by two hours after administration the RSNA was reduced by 37 ± 12% (figure 7.1). This 
contrasts with responses observed following saline, or either hormone alone (figure 7.1). 
Leptin or insulin alone increased RSNA (figure 7.1). 
7.3.1.2 Effect on MAP and HR 
When insulin and leptin were combined there was a small increase in MAP (figure 7.2), 
which was significantly different compared to saline and to the administration of the 
hormones alone (P<0.0001 between the groups) (figure 7.2). 
With respect to the HR response, the combination of leptin and insulin induced a small 
increase, which was significantly less than the saline (control) (P<0.0001) (figure 7.2). 
The resting levels of MAP and HR prior to hormone administration were not significantly 
different between groups (figure 7.3). 
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Figure 7.1 Percent change in RSNA induced by leptin and insulin alone and in combination 
in rats fed a high fat diet (HFD). 
 
Percent change in renal sympathetic nerve activity (RSNA) from baseline levels over time in 
rats fed a high fat diet (HFD) after intracerebroventricular injection of leptin (n=4) (7μg/5μl), 
insulin (n=5) (500 mU/5μl), control (saline, n=5) (5μl) and the combination of leptin and 
insulin (n=5). *P<0.0001 between groups. 
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Figure 7.2 Changes in MAP and HR induced by leptin and insulin alone and in combination 
in rats fed a high fat diet (HFD). 
 
Change in mean arterial pressure (MAP) and heart rate (HR) over time in rats fed a high fat 
diet (HFD) induced by the intracerebroventricular administration of leptin (n=4) (7μg/5μl), 
insulin (n=5) (500 mU/5μl), control (saline, n=5) (5μl) and the combination of leptin and 
insulin (n=5). *P<0.0001 between groups. 
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Figure 7.3 Basal level of MAP and HR in rats fed a high fat diet (HFD) or normal diet (ND). 
 
 
Basal levels of mean arterial pressure (MAP) heart rate (HR) in rats fed normal chow diet 
(ND; open bar) and high fat diet (HFD; black bar) before intracerebroventricular 
administration of leptin (n=4) (7μg/5μl), insulin (n=5) (500 mU/5μl) and the combination of 
both hormones (n=5). 
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7.3.2 Comparison of responses to the combination of insulin and leptin in rats fed high 
fat vs normal chow diets 
7.3.2.1 RSNA 
In rats fed a HFD, the response to RSNA induced by the ICV administration of insulin and 
leptin combined was in stark contrast to that observed in rats fed a ND. In HFD, the reduction 
in RSNA was significantly different to the increase in RSNA induced by the combination of 
leptin and insulin in rats fed a ND (P<0.0001) (figure 7.4). 
7.3.2.2 MAP and HR 
The MAP response over time induced by the combination of insulin and leptin was 
significantly higher in rats fed a HFD compared to rats fed a ND (P<0.0001) (figure 7.4). 
However, the response to the combination of insulin and leptin on the HR over time was not 
significantly different between rats fed the different diets (figure 7.4). In both groups the time 
courses for HR over time were similar. 
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Figure 7.4 RSNA, MAP and HR response following leptin and insulin alone and in 
combination in rats fed a high fat diet (HFD) or normal diet (ND). 
 
Renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP) and heart rate (HR) 
responses between rats fed a normal chow (ND) and a high fat diet (HFD), induced by 
intracerebroventricularly administered leptin (n=5 ND, n=4 HFD) (7 μg/5 μl), insulin (n=6 
ND, n=5 HFD) (500 mU/5μl) and the combination of leptin and insulin (n=4 ND, n=5 HFD). 
*P<0.0001 compared to ND. 
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7.4 DISCUSSION 
The main finding of this study is that the ICV administration of leptin and insulin combined 
in rats fed a HFD significantly decreased RSNA in comparison to either hormone alone or 
saline. MAP, however, was significantly increased compared to either hormone alone. 
In HFD, leptin alone induced an increase in RSNA, this was reported in our previous work in 
chapter 5 and also by others (17, 18, 58, 79, 87, 275). Similarly, insulin alone also induced 
increases in RSNA and is in agreement with work in mice (53). In ND, similarly, leptin or 
insulin alone induced increases in RSNA. This is in agreement with others (53, 54, 73, 99, 
100, 102, 110, 256, 274). 
Leptin or insulin alone acts centrally to increase RSNA through a similar mechanism 
involving activation of melanocortin 4 receptors (MC4R) in the brain (110). Therefore, one 
could hypothesise an interaction where insulin and leptin combined induced a greater 
sympatho-excitatory action on RSNA. Indeed in ND, we found previously in chapter 4, that 
leptin and insulin combined induced greater increases in RSNA compared to either hormone 
alone (274). 
Surprisingly, in the present study in HFD rats, leptin and insulin in combination did not 
induce a sympatho-excitatory effect on RSNA. Therefore, HFD can influence the RSNA 
response to leptin and insulin combined such that, a sympatho-excitatory response (seen in 
ND) is converted to a sympatho-inhibitory response by HFD. 
In contrast to the effects on RSNA, in rats fed a HFD, blood pressure was elevated slightly 
but significantly following the combination of leptin and insulin. This suggests that leptin and 
insulin may be elevating blood pressure through outputs/mechanisms other than RSNA. 
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This present study found that acute central administration of insulin and leptin combined 
increased HR. This response was similar to ND groups, indicating that the HR response was 
not altered by HFD, in contrast to RSNA. Thus, the present findings suggest that HFD can 
selectively influence different outputs following the combination of leptin and insulin. A 
possible explanation could be that HFD is having an effect on baroreflex sensitivity of RSNA 
during the MAP increases, resulting in inhibiting RSNA. However, It has been shown that 
HFD can decrease the sensitivity of the RSNA baroreflex response (279), suggesting that this 
is an unlikely explanation for our observation. Thus, the exact mechanisms mediating this 
interesting observation, however, are unknown, and further investigation is needed. 
In conclusion, the main finding of the present study is that the combination of both insulin 
and leptin significantly decreased RSNA when administered centrally in rats fed a HFD. 
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8 Chapter 8: General discussion and conclusion 
In this thesis, we investigated the effects of central administration of leptin, resistin and 
insulin alone, and in combination on renal sympathetic nerve activity (RSNA), mean arterial 
pressure (MAP) and heart rate (HR). The findings of this thesis show, for the first time, that 
resistin acts centrally to influence the RSNA in rats fed a high fat diet (HFD), and this effect 
was similar to the response in rats fed a normal chow diet (ND). In addition, I showed that 
leptin acts centrally to increase RSNA in ND and HFD, confirming previous work in the 
literature (17, 18, 58, 79, 87). It was also shown that in rats fed a ND or HFD, leptin 
combined with resistin induced greater increases in RSNA compared to each hormone alone. 
In this thesis, I found for the first time in rats fed a HFD that central administration of insulin 
increased RSNA significantly, but this effect was less than in rats fed a ND. Furthermore, 
leptin and insulin combined in rats fed a ND induced greater increases in RSNA compared to 
either hormone alone. In contrast, in rats fed a HFD leptin and insulin combined reduced 
RSNA. 
Finally, I also investigated the effect of resistin and insulin combined. In ND rats there was 
no increase in RSNA, but in HFD fed rats RSNA fell significantly. In table 8.1, I summarise 
the main findings of this present work, and it shows that the knowledge gaps highlighted in 
the aims in table 1.1 have now been filled. 
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Table 8.1 Summary of the effects of leptin, insulin and resistin on RSNA in rats fed a normal 
diet or a high fat diet. 
 
Hormones Normal Diet - RSNA High Fat Diet - RSNA 
Leptin     
Insulin   ↑ 
Resistin     
Leptin + resistin     
Leptin + insulin     
Resistin + insulin ▬   
↑smaller increase;  increase;  greater increase;   ▬no change;  greater decrease. 
 
Prior to the current work, no previous studies investigated the cardiovascular effects of 
resistin in HFD conditions. In this thesis, it was found that resistin increased RSNA in HFD. 
This effect was similar to ND, suggesting that the effects of resistin on RSNA are not 
attenuated by HFD. Similarly, the RSNA response to leptin was not attenuated in ND and 
HFD. 
In rats fed a ND, the combination of leptin and resistin induced a greater sympatho-excitatory 
on RSNA response when compared to each hormone alone. This response was also observed 
in rats fed a HFD. This key finding suggests that HFD does not influence the sensitivity of 
the responses to leptin and resistin combined. Thus, in conditions such as overweight/obesity, 
where these hormones are elevated, the sympatho-excitatory responses of the interaction of 
leptin and resistin may be important and may contribute to the cardiovascular complications 
observed in those conditions. 
In this study, for the first time, it was shown that insulin acts centrally to increase RSNA in 
rats fed a HFD. However, this effect was less than that seen in ND. Therefore, our result 
suggests that the HFD attenuates the RSNA response. This finding is in agreement with the 
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recent work from Rahmouni’s laboratory in mice (53), but both studies contrast with earlier 
work on mice that showed no attenuation by HFD (110). 
Insulin and leptin alone increased RSNA. Since both hormones share a common pathway to 
elicit this response (110), it is possible that an interaction between these hormones may occur, 
as seen with the combination of leptin and resistin. Furthermore, since HFD attenuated the 
RSNA response following insulin, it was of interest to see whether HFD affected the RSNA 
response when insulin and leptin were combined. 
I found in rats fed a ND, that the central administration of leptin and insulin combined 
increased RSNA compared to leptin or insulin alone. This was similar to the interaction seen 
with leptin and resistin combined in ND. In both cases, the responses were at least additive. 
However, in HFD rather than an increase in RSNA, there was a reduction following the 
combination of leptin and insulin. This suggests that HFD in some way converts a sympatho-
excitatory effect to a sympatho-inhibitory response. 
Similarly, the combination of resistin and insulin also reduced RSNA in rats fed a HFD, but 
in ND fed rats, there was no change in RSNA following resistin and insulin combined. This 
suggests that insulin and resistin combined mutually inhibit their sympatho-excitatory 
actions, and HFD in some way enables the expression of a sympatho-inhibitory response. The 
implication of these complex interactions are discussed further below. 
In this thesis, the changes in MAP and HR did not correlate with the clear changes in RSNA 
observed. This may be due to the fact that this work investigated acute responses of these 
hormones, whilst chronic studies suggest more consistent changes in blood pressure and HR 
particularly with leptin (103, 104, 193, 195). 
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Perspective 
Plasma levels of leptin, resistin and insulin are increased in overweight/obese conditions (79, 
85-87, 127, 128, 161, 162). These hormones can increase RSNA (51, 53, 54, 58, 99, 100, 
110). In overweight/obese conditions, RSNA is known to be increased abnormally (6, 7, 11, 
23, 35).  In the present work leptin and resistin combined increased RSNA in HFD, whereas 
the combination of leptin or resistin with insulin significantly reduced RSNA in HFD fed 
rats. Therefore, our results seem to suggest that HFD affects the sensitivity of the interaction 
of leptin or resistin with insulin on RSNA. Since RSNA is abnormally elevated in obesity our 
present results suggest that the sympatho-excitatory effects of leptin and resistin combined 
dominate over any sympatho-inhibitory actions induced by leptin or resistin combined with 
insulin. Future experiments in which the central effects of leptin, resistin and insulin 
combined together could be useful in clarifying this suggestion. 
Limitations and Future directions 
One of the main confounding factors that may implicate the results of the present work is the 
use of anesthetics. Anesthetics may affect the regulation of blood pressure and the autonomic 
nervous system. Thus, performing these experiments in conscious animals may be 
advantageous. Another limitation is the use of short-term acute administration of the 
hormones in the present study. Although, we did see changes in RSNA with the use of short-
term acute administration, the use of chronic long-term infusion of the hormones would be an 
excellent extension of the present work that could provide valuable insight into the chronic 
regulation of RSNA and MAP. 
Additionally, we have injected the hormones directly into the CSF, and this method is 
important to investigate the central action of the hormones. It is important to note that these 
hormones also circulate in the blood and their access to the brain may differ compared to ICV 
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injection. Thus, futures studies could be directed to comparisons of intravenous (IV) vs ICV 
administration. 
Finally, we discovered novel interactions between (leptin + insulin), (resistin + insulin) and 
(leptin + resistin). Therefore, future studies investigating the effects of these three hormones 
together could be valuable. Extending the sympathetic nerve activity outputs to include 
nerves to other organs may also provide insight into whether the observations we made with 
RSNA are selective or more generalized to other outputs. 
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